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Summary
T ransmembrane proteins span biological membranes and provide essen-tial functions to the cell. Here we provide structural insight into three
transmembrane proteins involved in substrate transport and signal transduc-
tion. Our goal is to understand the mechanism underlying the function of
those proteins and to contribute thereby to improvements for future medical
treatments.
P-glycoprotein 1 (Pgp) is an ABC transporter involved in multidrug trans-
port. It provides protection from potentially toxic substances by exporting
them from the cell. However in cancer cells upregulation of Pgp expression
can interfere with therapy. Here we provide a near-atomic resolution struc-
ture of cross-linked nucleotide free Pgp interacting with UIC2, an inhibitory
antibody, and the third generation Pgp inhibitor zosuquidar. Our structure
shows binding of two zosuquidar molecules in the transmembrane domain of
an occluded conformation. In addition we describe the binding interface of
UIC2 binding, providing insight to the mechanism of conformational trapping.
Characterized binding interfaces may be exploited for therapeutic purposes.
BSEP is the only bile salt transporter at the canalicular membrane of hepato-
cytes. Despite a very high sequence identity compared to Pgp, BSEP is way
more selective. While diseases effected by mutations in BSEP are considerably
rare, inhibition of BSEP can be the result of not intended interactions between
BSEP and a variety of pharmaceutical compounds. I determined four struc-
tures of BSEP including a drug inhibited state using the antidiabetic drug
glibenclamide and two structures in presence of the substrate taurocholate.
These structures give rise to multiple potential models for the transport mech-
anism. In addition I could show that glibenclamide binds to the cytosolic
facing cavity of BSEP, either repressing the connecting loop between the N-
and C-terminal BSEP or locking BSEP in a inside open conformation. In
addition mutations of BSEP associated with disease could be explained on
structural basis.
NCX are a sodium/calcium exchangers widely spread among species, involved
in calcium signalling. We have solved two crystal structures of the bacterial
NCX from Thermotoga maritima in the outward facing conformation. Both
conformations are substrate free, but show differences in the ion binding site.
Comparison of our structures the NCX homolog from Methanococcus jan-
naschii suggest a simple reorientation of N-termianl helix 7 to switch NCX
to the occluded state, indicating transition to the inward facing site.
i
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1 Introduction for ABC Transporters and P-glycoproteine 1
T his introduction aims to give an overview for ABC transporters in general,but focussing more on exporters. In addition a introduction is given
specific for Pgp, discussed in detain in the next chapter.
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1.1 Structure Of ABC Transporters
ABC transporters build a family of membrane proteins having a cytosolic ATP
binding cassette. The ABC transporter superfamily is divided to 7 subfamilies
comprising ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, and White. De-
spite classification in one family, there is evidence for a polyphyletic origin of
the transmembrane domains. Statistical sequence analyses indicate that the
membrane spanning domains of ABC exporters have evolved independently al
least three times ([1]). These origin from a triplication of a 2 transmembrane
segment (TMS), a duplication of a 3 TMS and a duplication of a 4TMS pre-
cursor. Emerging domains comprise 8-10 TMS for the duplication of 4TMS
precursors and 6 TMS for the other cases. For ABC importers a polyphyletic
origin of transmembrane domains can be assumed based on structural evi-
dence ([2]). ABC transporters promote active transport of substrate across
the membrane driven by ATP binding and hydrolysis. This transport can take
place against strong gradients. ABC transporters are widely spread among
species. In bacteria uptake of nutrients, secretion of toxins to provide antibi-
otic resistance or as virulence factors are widely covered by ABC transporters
([3]). In eukaryotes no ABC importers are present, but exporters are involved
in multiple processes from which clearance of potentially toxic compounds by
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Figure 1: Schematic structure of some ABC transporters. A Transporter consist
of four separate domains. B Transporter consist of two separate trans-
membrane domains (TMD) and two fused ATPase domains. C In full
transporters all domains are part of the same polypeptide chain. D Half
transporters consist of two copies of a TMD fused to a ATPase domain.
Figure redrawn and adapted from [4]
ABC transporters of the MDR family is most prominent feature. Depend-
ing on the task, substrate specificity can be very broad or limited to a single
target. With the exception of importers, ABC transporters consist of two
transmembrane units and two ATPase units. In bacteria, ABC transporters
are usually composed of four independent subunits (Figure 1A) or of two inde-
pendent transmembrane domains and two fused ATPase domains (Figure 1B).
Animal and fungal ABC transporters on the other hand generally consist of
a single polypeptide chain with all four domains fused together (Figure 1C)
as full transporters or a ATPase and a transmembrane domain fused as half
transporter (Figure 1D) ([4]). The ATPase domains of ABC transporters, also
called nucleotide binding domains (NBDs), consist of an assembly of differ-
ent motifs to bind and hydrolyze ATP. Best known are the Walker A and B
motif ([5]). The Walker A motif consists of a α-helix, followed by a glycine
rich loop, whereas the Walker B motif is build of a β-strand. Between the
Walker A and B motif lies the C motif, also known as LSGGQ or signature
motif. This motif is the hallmark of ABC transporters and participates in
ATP binding. The serine side chain in the LSGGQ motif interacts with the γ-
phosphate for coordination. The Walter A motif of one domain interacts with
the LSGGQ motif of the other domain to bind ATP. This leads to a dimeriza-
tion ([6]). The Walker B motif on the other hand is taking part in hydrolyzing
ATP, providing a glutamate for the nucleophilic attack ([7]). The EAA loop
of the TMD couples ATPase domain activity with the transmembrane domain
through interactions with the Q-loop of the ATPase domain ([8]). The largest
conformational change takes place upon binding of ATP and not hydrolysis as
initially assumed ([9]).
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ABC transporters translocate their substrate over a membrane using ATP as
driving force. ATP binding and hydrolysis takes place at the cytosolic nu-
cleotide binding domains. The Walker A motif of one NBD and the signature
sequence of the other NBD jointly bind an ATP molecule. Thereby a lysine of
the Walker A motif interacts with oxygens of beta/gamma-phosphate of the
ATP and aromatic residues of this motif take part in binding the adenine moi-
ety of ATP ([10]). The gamma-phosphate interacts also with serine and glycine
of the signature motif ([10], [11]). ATP has to be properly oriented to allow
hydrolysis by the attacking water molecule ([8]). ATP hydrolysis takes place
at the Walker B motif. Therefore a glutamate of the Walker B motif performs
a nucleophilic attack on the ATP γ-phosphate ([7]). The exact mechanism is
still elusive ([12]). A coordination network is needed for hydrolysis, including
the beta- and gamma-phosphate of ATP, Mg2+, the C-terminal aspartate and
glutamate of the walker B motif, a glutamine of the Q-loop and multiple water
molecules. ([12], [13], [14], [8], [15]). For some ABC transporters, including
Pgp, a model of alternate ATP hydrolysis by NBD1 and NBD2 is proposed
([16]). For other transporters mutating one NBD does abolish transport activ-
ity, but mutating the other domain does not. This disagrees with a sequential
process ([17], [18]).
Different models were proposed for the transport mechanism. Due to the broad
range of transported substrates and the assumed polyphyletic origin of trans-
membrane domains multiple transport mechanisms might coexist. The flipflop
mechanism is proposed for the transport of lipids or lipophilic molecules.
Hereby the substrate is transported from one membrane leaflet to the other,
including a change of the substrates orientation ([19]). An alternative model
for the transport uses the alternative access model. For this model an outward
open and an inward open conformation with different substrate affinities are
assumed. For importers the inward open structure has a lower affinity for sub-
strate binding. For exporters correspondingly the outward open conformation
binds substrate weaker for release. In this model ATP binding and hydrolysis
brings in the energy to switch between the two conformations, but transport
is not mediated through the rearrangement of the transmembrane domains
induced by ATP hydrolysis ([8]). The ATP-switch model assumes that the
conformational change induced by ATP binding and hydrolysis effect substrate
transport. Initial binding of the substrate leads to subtle rearrangements of
the TMDs. These rearrangements increase the affinity of the NBDs for ATP
binding. Dimerization of the NBDs is induced by ATP binding. Thereby the
transporter changes from an inward open to an outward open conformation
3
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to release the substrate. Subsequently ATP is hydrolysed and released to re-
cover the initial inward open conformation ([20]). This model can be extended
by an involvement of ATP hydrolysis to the release of a substrate. Another
model is called vacuum cleaner model. It is a combination of the flipflop and
ATP-switch model ([21]). Thereby the substrate enters the transporter from
a membrane leaflet and is removed from the membrane.
1.3 P-glycoprotein 1
Pgp refers to permeability-glycoproteine. It belongs to the family of ABC-
transporters, in particular to the MDR/TAP subfamily. Pgp spans 1280 amino
acids and has the size of 141kDa and is decorated by an additionally glyco-
sylation of 10-15kDa. Pgp exports harmful substances, in particular xenobi-
otics. This requires a vast flexibility to adapt to a broad range of compounds,
without exporting physiologically relevant compounds. As xenobiotics are not
restricted to certain features, there is no particular evolutionary adaption to
the substrate possible. The encoding gene is known as MDR1 for the involve-
ment of Pgp in multidrug resistance in cancer cells. Thereby overexpression
of Pgp1 promotes resistance against certain antineoplastic drugs. This resis-
tance is based on the ability to extrude a large range of anticancer drugs ([22]).
Pgp transports preferably large uncharged amphipathic substrates like pacli-
taxel or doxorubicine. A typical feature is not known, thought aromatic rings,
overall high hydrophobicity and tertiary amino groups are found in many sub-
strates ([22], [23], [24], [25]). Amphipathic drugs are supposed to integrate
into the outer membrane leaflet with the hydrophobic part. From there these
drugs move to the inner leaflet by a flip-flop action. This process is rather
slow giving Pgp enough time to handle drug influx. ([26], [27]). The speed
of drug influx is important due to the low turnover of Pgp ([28], [29]). While
for amphipathic substrates a cytosolic access could be optional, hydrophobic
substrates probably enter Pgp from the inner leaflet only ([30], [31]).
To date no loss of function mutations are known for human Pgp, implying a
clear necessity of its function. However studies in mice showed that a mutation
of murine Pgp homologs has no effect on viability, unless these mice are exposed
to drugs ([32], [33], [34]). There is a wide overlap of transported substrate
with other transporters like ABCC1, ABCC2and ABCG2 ([35]), as well as
with CYP2A4, a drug-metabolizing enzyme.
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Pgp1 is expressed at multiple sites either to eliminate xenobiotics from the
body or to protect exclusive vital organs.
Pgp is found on the apical side of mucosal cells of the intestine from duode-
num to rectum ([36], [37], [38]). In the mucosa of the gut Pgp prevents entry
of xenobiotics into the body. It does not only interfere with the uptake of
amphipathic drugs ([39], [40], [41]), but also excretes intravenously adminis-
tered drugs ([42], [43]). Interference with orally applied drugs can be strong
enough to enforce intravenous administration or simultaneous treatment with
Pgp inhibitors ([44]). In addition dietary components can modulate activity
or availability of Pgp, modulating drug uptake ([45], [46]).
In the liver Pgp1 is expressed at the canalicular membrane of hepatocytes.
There it takes part in the clearance of xenobiotics from the body by secretion
into bile. The hepatic expression level of Pgp1 is individual and can differ by
a factor of 50 ([47]). Nevertheless Pgp expression is in average sevenfold lower
than in the small intestine ([48]).
Further Pgp is expressed at the luminal side of renal tubular cells to excrete
xenobiotics and lipophilic drugs ([49]). Similar to hepatic and intestinal ex-
pression, renal Pgp is intended to purge toxic substances from the body.
The CNS is vital for survival. Therefore the blood-brain barrier adds safety
layer to protect the brain from potentially toxic substances. In brain capillar-
ies, endothelial cells are connected by tight junctions. These tight junctions
prevent paracellular transport and enforce transcellular transport. An involve-
ment of Pgp in the blood-brain barrier could be shown with mutant mice, being
more sensitive to neurotoxic pesticide than wildtype mice ([50], [51]). Pgp re-
duces the accumulation of diverse drugs like paclitaxel, vincristine, digoxin or
loperamide ([52], [53], [54]). It appears that current inhibitors are not able
to inhibit Pgp at high expression levels as they are found in the blood-brain
barrier.
In the placenta the fetus is protected by Pgp expression in fetus-derived ep-
ithelial cells of the placenta. Pgp1 is expressed in trophoblasts to protect the
embryo from xenobiotics and other toxics. The trophoblasts proliferate to
cytotrophoblasts and syncytiotrophoblasts, which build up the chorionic villi
([55]). The chorionic villi are in contact with maternal blood, filling the in-
tervillous space. Pgp in the apical membrane of these cells protect the fetus
against amphipathic toxins ([56]). In a mouse model Pgp mutants were more
5
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sensitive to the teratogenic effect of avermectin ([57]).
Pgp1 is expressed in lymphocytes and in hematopoietic stem cells. The efflux
might protect these cells from toxins ([58], [59]). On the other hand Pgp1
contributes to drug resistance in leukemia ([60]) and HIV treatment ([61]).
In cancer cells, upregulation of Pgp expression might promote drug resistance.
Expression of Pgp is detected by immunohistochemistry. This assessment is
error prone due to possible false positive signals from infiltrating macrophages
and T cells. The impact of Pgp inhibition for cancer treatment is still un-
certain. On one hand inhibitors used in early studies have a poor inhibitory
performance leading to an underestimation of the effect of Pgp inhibition on
cancer treatment. On the other hand Pgp inhibitors also affect drug elimina-
tion in intestine, kidney and liver. Therefore effects can be based on the higher
abundance of the tested drug in the body, instead of impaired clearance from
the tumor. ([18])
1.5 Genetic Polymorphism
The gene coding for Pgp1 holds 28 exons giving rise to 3843nt of coding RNA.
To date about 100 single nucleotide polymorphisms (SNPs) have been iden-
tified in the coding region. At least 16 polymorphisms could be found in
Germany ([62], [63]) and 9 in Japan ([64], [65]). In humans no null allele was
detected so far. This is surprising based on the fact, that Pgp inhibition does
not provoke a phenotype in absence of amphiphilic toxins. In mice and collies
null alleles have been found, rendering them hypersensitive to ivermectin, a
drug against nematode infections ([51], [66]). In addition, the progeny of het-
erozygous Pgp null mutant mice treated with the teratogenic ivermectin show
phenotypes depending on the embryos genotype. Progeny of homozygous null
mutant genotype (Mdr1a -/-) had a cleft palate, whereas homozygous wildtype
progeny (Mdr1a +/+) showed no defects. In case of the heterozygous progeny
(Mdr1a +/-) 30% had a cleft palate ([57]). This shows the dose dependency of
Pgp substrates and potential implication of different alleles on drug response
based on Pgp abundance and activity.
Following SNPs represents a subset, which was investigated more in depth.
The SNP 2677G>T/A codes for an alanine, a threonine or a serine at position
893. Despite similar expression levels this SNP shows significant differences
in the transport properties. Vmax for the transport of vincristine with S893 is
50% faster than in A893. For T893 Vmax exceeds 893A by 200% ([67]). This is
consistent with a better response of the 2677G allele for treatment of chronic
6
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myeloid leukemia with the drug imatinib ([68]). The SNP 1236C>T does
not change the primary sequence of Pgp1. But still homozygosity of 1236T
increases the response to imatinib in chronic myeloid leukemia ([68]). The
silent C3435T mutation coding for isoleucine leads to a reduced abundance
of Pgp in the intestine. This reduction correlates with digoxin uptake ([62]).
Prevalence of 3435T differs between ethnic groups from 20-25% in African
blacks to 55-75% in Caucasians ([69], [70]). This might influence interethnic
variation in drug response ([71]). The missense SNP 1199G>T mutates the
serine at position 400 to an isoleucine. Ile400 is associated with a four times
lower in vitro substrate transport capacity. On the other hand SNP 1199A
coding for a asparagine at position 400 increased resistance to tested Pgp1
substrates ([72]). The mutation G191R induced by SNP G571A reduces Pgp1
mediated resistance against vinblastine, vincristine, paclitaxel, and etoposide
by a factor of 5. However, transport of doxorubicin and daunorubicin is not
affected ([73]).
The influence of SNPs on the response to drugs remain partially contradictory.
Due to the vast amount of SNPs in Pgp1 and the broad range of transported
substrates, studies cover only a subset of possible combinations. Currently no
prediction can be made for the pharmacokinetic based on a patients morph.
1.6 Activation of P-glycoprotein 1 by Xenobiotics
A plethora of pathways has been shown to take part in regulating of Pgp
expression, among them NF-KB and MAPK signaling pathways ([74], [75]).
Substrates can induce ABCB1 expression via PXR/RXR (pregnane X recep-
tor / retinoic acid receptor). PXR is a nuclear receptor capable to sense
xenobiotics and to activate transcription of detoxification components as het-
erodimer with RXR. This is in line with the coexpression of Pgp with proteins
of the cytochrome P450 3A family, which have been shown to be regulated by
PXR ([76], [77], [48]). Transcriptional activation has been shown for PXR/-
CAR (constitutive androstane receptor) ligands as well ([78]). This can in-
duce enhanced drug efflux of co-administered drugs ([43]). On the other hand
drugs having an inhibitory effect on Pgp1 can increase bioavailability of co-
administered drugs ([79]). This effect can be used to increase therapy efficiency,
but leads as well to a risk of an overdose when drugs are combined ([80]).
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Class Drug
Substrate:
Anticancer drugs Docetacel, doxorubicin, etoposide, imatinib, paclitaxel,teniposide, vinblastine, vincristine
Steroids Dexamethasone, methylprednisolone
Immunosuppressants Cyclosporine, sirolimus, tacrolimus
HIV protease inhibitors Amprenavir, indinavir, nelfinavir, saquinavir, ritonavir
Antibiotics Erythromycin, levofloxacin, ofloxacin
β-blockers Bunitrolol, carvedilol, celiprolol, tanilolol
Ca2+-channel blockers Diltiazem, verapamil
Cardiac drugs Digoxin, digitoxin, quinidine
Inducers:
Anticonvulsants Carbamazepine, phenytoin, phenobarbital, primidon
Tuberculostatics Rifampicin
Herbals Hyperforin (constituent of St. John’s wort)
Inhibitors:
Calcium channel antagonisten Verapamil
Makrolide antibiotics Erythromycin, clarythromycin, not azithromycin
HIV protease inhibitors Ritonavir
Immunosuppressents Cyclosporin
Antiarrhythmics Chinidin, propafenon
Table 1: Substrates, inducers, and inhibitors of P-glycoprotein 1. Table redrawn in
reduced form from ([82])
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My contribution to this work comprised initial screening by negative stain and
structure determination of the flexible ABCB1HM -UIC2.
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2 P-GLYCOPROTEIN
Significance
The ATP binding cassette transporter ABCB1 (also termed P-glycoprotein)
is a physiologically essential multidrug efflux transporter of key relevance to
biomedicine. Here, we report the conformational trapping and structural anal-
ysis of ABCB1 in complex with the antigen-binding fragment of UIC2, a hu-
man ABCB1-specific inhibitory antibody, and zosuquidar, a third-generation
ABCB1 inhibitor. The structures outline key features underlining specific
ABCB1 inhibition by antibodies and small molecules, including a dual mode
of inhibitor binding in a fully occluded ABCB1 cavity. Finally, our analysis
sheds light on the conformational transitions undergone by the transporter to
reach the inhibitor-bound state.
Keywords: ABC transporter, structure, small-molecule inhibitors, cryo-EM,
mechanism
2.1 Abstract
The multidrug transporter ABCB1 (P-glycoprotein) is an ATP-binding cas-
sette transporter that has a key role in protecting tissues from toxic insult and
contributes to multidrug extrusion from cancer cells. Here, we report the near-
atomic resolution cryo-EM structure of nucleotide-free ABCB1 trapped by an
engineered disulfide cross-link between the nucleotide-binding domains (NBDs)
and bound to the antigen-binding fragment of the human-specific inhibitory
antibody UIC2 and to the third-generation ABCB1 inhibitor zosuquidar. Our
structure reveals the transporter in an occluded conformation with a central,
enclosed, inhibitor-binding pocket lined by residues from all transmembrane
(TM) helices of ABCB1. The pocket spans almost the entire width of the lipid
membrane and is occupied exclusively by two closely interacting zosuquidar
molecules. The external, conformational epitope facilitating UIC2 binding is
also visualized, providing a basis for its inhibition of substrate efflux. Ad-
ditional cryo-EM structures suggest concerted movement of TM helices from
both halves of the transporters associated with closing the NBD gap, as well
as zosuquidar binding. Our results define distinct recognition interfaces of
ABCB1 inhibitory agents, which may be exploited for therapeutic purposes.
P-glycoprotein (ABCB1) is an ATP-binding cassette transporter ubiquitously
expressed in a wide range of cells and tissues, where it has an important role
in cellular detoxification ([81], [18]). Its wide substrate specificity underlies
its physiological relevance in drug transport across multiple blood-organ bar-
riers, resulting in modulation of drug delivery, drug-drug interactions, and
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drug pharmacokinetics for a host of clinically active agents ([81], [18], [82],
[83]). ABCB1-mediated drug efflux has been linked to multidrug resistance,
adversely affecting cancer chemotherapeutic treatment and treatment of vari-
ous brain disorders ([84], [85], [86]). The ABCB1-specific inhibitory antibody
UIC2 was developed with the goal of increasing antitumor drug treatment ef-
ficacy ([87], [88]). UIC2 targets the extracellular moiety of human ABCB1
(ABCB1H) and has been successfully used to investigate the transport cycle
of ABCB1 owing to its ability to bind the transporter during various states
of the catalytic cycle ([88], [89], [90]). Although the crystal structure of the
antigen-binding fragment (Fab) of UIC2 has been determined ([91]), the con-
formational epitope on the surface of ABCB1H has remained elusive because
direct visualization of the ABCB1-UIC2 interface was limited to low-resolution
cryo-EM reconstructions ([92]). To date, several structures of mouse ABCB1
are available, including those with bound inhibitors ([93], [94], [95], [96]) and
nucleotides ([97]). However, despite added ligands, all these reveal the trans-
porter in an inward-open conformation with varying degrees of nucleotide-
binding domain (NBD) separation and a largely unchanged transmembrane
domain (TMD) and substrate translocation pathway.
Small-molecule, third-generation inhibitors, including zosuquidar, tariquidar,
and elacridar ([98], [99], [100]), have shown potential in model systems for
coadministration with various anticancer agents. However, antibody- and
small-molecule inhibitor-based strategies have not been successfully utilized
clinically ([101], [102]), emphasizing the need for designing more effective ther-
apeutic and diagnostic strategies targeting ABCB1 expression and inhibition.
A detailed understanding of the structure of ABCB1 with bound antibody
fragments and drugs/inhibitors in different conformations is central to im-
proving the specificity of inhibitors and to further our understanding of the
chemistry governing ABCB1 interaction with high-potency inhibitors. To
achieve this, we generated a hybrid construct of human and mouse ABCB1
(ABCB1HM) that contains the extracellular region of the human protein, in-
cluding the recognition epitope of UIC2, on a background of mouse ABCB1.
ABCB1HM shares ~90% sequence identity with the human protein (SI Ap-
pendix, Section 2.5) and takes advantage of the higher biochemical stability
of mouse ABCB1, which shares high sequence similarity and, except for sub-
tle differences, exhibits highly similar substrate/inhibitor-binding properties
with its human homolog, especially with regard to third-generation inhibitors
([103]). As highlighted in Figure 2 and SI Appendix, Figure 6, our results
reveal key ABCB1H-specific residues involved in the interaction interfaces of
both zosuquidar and UIC2 and ABCB1. ABCB1 has been observed to exist in
a range of conformations with varying degrees of NBD separation, including
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a nucleotide-bound "closed" conformation, where no gap between NBDs exists
([92]). To understand its interaction with small molecules, we sought to vi-
sualize an intermediate conformation of the transporter, where the NBD gap
has been partially, but not fully, closed. To visualize and analyze the effect of
progressive NBD gap closure on the TMD domains (in the absence of bound
nucleotides in this case), we therefore generated a variant that allowed disul-
fide cross-linking of the NBDs of the transporter (ABCB1HM−X). The latter
harbors two S → C mutations at positions 559 and 1,204 in the dimerization
(D)-loops, expected to come within close proximity to each other upon NBD
dimerization as seen in the canonical ABC exporter Sav1866, among others,
and successfully used for conformational trapping and high-resolution analysis
of other ABC transporters ([104], [105]).
2.2 Results
2.2.1 Conformational Trapping and Functional Characterization of ABCB1HM
ABCB1HM−X was shown in vivo to confer up to 50-fold higher paclitaxel re-
sistance to mammalian cells when expressed in an inducible HEK293 cell line
compared with uninduced cells (SI Appendix, Figure 7A), showing that the
construct retains paclitaxel transport activity. The construct is strongly in-
hibited by zosuquidar and UIC2, which resensitize ABCB1HM−X-expressing
cells to paclitaxel (Figure 2Fig. 1 B and C) at nanomolar concentrations. The
constructs were expressed in HEK293 cells and purified in a lauryl maltose
neopentyl glycol (LMNG) and cholesteryl hemisuccinate (CHS) mixture in con-
trast to the more commonly used dodecyl maltoside (DDM)-based preparations
to avoid interference from nonspecifically bound DDM molecules in the trans-
membrane (TM) ligand-binding cavity. Disulfide cross-linking of ABCB1HM−X
was nearly complete in the absence of added nucleotides, as revealed by gel
electrophoresis (SI Appendix, Figure 7B), and ABCB1H , ABCB1HM , and
cross-linked or reduced ABCB1HM−X all showed near-identical UIC2-binding
affinities (SI Appendix, Figure 7C).
While previous studies have reported negligible basal ATPase rates for detergent-
purified ABCB1 ([106]), our LMNG/CHS-purified ABCB1H and ABCB1HM
constructs maintain a measurable, albeit low, basal ATPase rate (~20-30 nmol·
min−1·mg−1), which is stimulated up to 10-fold by addition of zosuquidar or
the anticancer drug paclitaxel (SI Appendix, Figure 7D), allowing for char-
acterization of drug-mediated ATPase activity in an identical environment as
used for our structural analysis. Although disulfide cross-linking did not alter
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Figure 2: Structural and functional characterization of UIC2-Fab and zosuquidar-
bound ABCB1. (A) Topology diagram of ABCB1. TM helices are num-
bered, and their relative lengths, as well as the locations of kinks or bends,
are schematically illustrated. The locations of residues interacting with
bound zosuquidar are schematically shown as filled green circles. External
loops EL1, EL3, and EL4 interact with bound UIC2-Fab, as indicated by
red lines. C, carboxy terminus; c.h., coupling helices; e.h., elbow helices;
N, amino terminus. (B) Inhibition of ABCB1HM−X -mediated protection
from paclitaxel by zosuquidar (n = 3, error bars represent SD). (C) Inhibi-
tion of ABCB1HM−X -mediated protection from paclitaxel by UIC2 (n =
3, error bars represent SD). (D) Ribbon representation of the UIC2-bound
ABCB1HM−X structure, with the two halves of ABCB1 colored yellow
and orange, respectively, and the heavy (HC) and light (LC) chains of
UIC2-Fab colored blue and red, respectively. The approximate location
of the membrane is depicted in gray. Two bound zosuquidar molecules
are shown in light blue and pink sphere representation. The engineered
disulfide between the two NBDs is shown as black sticks.
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Km values for ATP hydrolysis in ABCB1HM−X and its ATPase stimulation
by zosuquidar, we observed a reduction in ATPase stimulation by paclitaxel
that could be reversed by addition of DTT (SI Appendix, Figure 7D and E).
Interestingly, zosuquidar has been shown to stimulate the ATPase rate of de-
tergent (DDM)-solubilized ABCB1 but inhibits the lipid-reconstituted ABCB1
ATPase rate, with the effect in the latter being much stronger (EC50 ~200 nM,
roughly 50-fold lower than that obtained in DDMmicelles) (24). This opposing
effect in detergent versus lipid has been speculated to stem from the occlusion
of a primary high-affinity zosuquidar-binding site by DDM molecules, leading
to zosuquidar binding to a secondary low-affinity site. As seen in SI Appendix,
Figure 7F, while the ATPase activity of both ABCB1H and ABCB1HM pu-
rified in LMNG/CHS is stimulated by zosuquidar, the EC50 values for this
modulation are ~200 nM, comparable to those reported for native membranes.
Combined with the absence of bound detergent molecules in our inhibitor-
bound structure, our results suggest that zosuquidar is bound to its primary
site in our studies, as explained below.
2.2.2 Overall Structure of ABCB1-UIC2 in Complex with Zosuquidar
The structure of cross-linked, zosuquidar-bound ABCB1HM−X was solved to
an overall resolution of 3.58Å [Fourier shell correlation (FSC) cutoff of 0.143]
(Figure 2D and Figure 8). The high disulfide trapping efficiency correlated well
with the observation that the overwhelming majority of usable particles corre-
sponded to a single conformation of ABCB1. The local resolution was highest
in the TM region, allowing unambiguous de novo building of the TMDs, in-
cluding the zosuquidar-binding pocket, as well as the ABCB1-UIC2 interface
(Figure 9). Despite their close association due to the disulfide cross-link, the
NBDs did not adopt a fully closed sandwich conformation, which is a hallmark
of ATP-bound structures, because no nucleotide was added. They maintained
a degree of conformational flexibility reflected in the lower resolution of the
electron density, nevertheless allowing atomic interpretation guided by the
structures of mouse ABCB1 previously reported with minor manual adjust-
ment where appropriate. Despite the overall lower resolution for the NBDs,
density for the introduced disulfide cross-link was visible. The NBD arrange-
ment was somewhat asymmetrical, closely matching that observed in the het-
erodimeric, bacterial homolog of ABCB1, TM287/288 ([107]). Asymmetry in
ABCB1 hydrolysis has previously been proposed ([97], [108]) and also observed
in a bacterial homolog of asymmetrical B family transporters, TmrAB ([109]).
Our structure revealed a single copy of UIC2-Fab bound to the external side of
the transporter and tilted by about 70° relative to the membrane plane (Fig-
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ure 2D). Whereas the architecture and fold of ABCB1HM are similar to those
of mouse ABCB1 ([94], [97]), the trapped conformation is distinct from previ-
ous structures because the NBDs are closer together and the TMDs assume a
conformation that provides structural insight into an occluded and inhibitor-
bound state of a B-family ABC exporter. As with previously reported ABCB1
structures, no density was observed for the linker region connecting the two
halves of the transporter.
2.2.3 Molecular Details of the ABCB1-UIC2-Binding Interface
UIC2 recognizes a conformational epitope of ABCB1 that involves residues
from TM1 and TM2 and the extracellular loops EL1, EL3, and EL4 (Figure 3A
and B), in agreement with biochemical studies that have identified the exter-
nal part of TM1 ([87]) and the external loop connecting TM5 and TM6 (EL3)
([90]) as contributing to the ABCB1H-UIC2 interface. The buried surface area
amounts to ~1,075Å2, with the heavy chain of UIC2-Fab forming the bulk of
the interface (~80%). The observed interactions include polar, electrostatic,
and hydrophobic contacts, including methionine-pi stacking. Differences in the
amino acid sequences of the external loops of ABCB1HM can readily explain
the specificity of UIC2 for the human protein over that of rodents (Figure 3C).
Additionally, the observed interaction provides a structural explanation of how
UIC2 inhibits transport activity of ABCB1: By clamping the external loops
together, UIC2 prevents ABCB1 from converting to an outward-open confor-
mation, which is required to release substrate to the outside ([110], [111]).
This is in line with studies indicating incomplete UIC2 binding in unmodified
ABCB1-expressing cells ([87]), where the transporter is expected to exist in a
mixture of conformations, including a UIC2-incompatible, outward-open state.
It also agrees with the observed modulation of UIC2 affinity for ABCB1 in the
presence or absence of various nucleotides and substrates ([90]). Any alteration
of the equilibrium between the outward-open and outward-closed conforma-
tions of ABCB1 caused by the binding or release of drugs/nucleotides as part
of the transporter’s catalytic cycle could alter its affinity for UIC2. As ABCB1
has previously been shown to hydrolyze ATP in the presence of UIC2 ([112]),
we conclude that the architecture of ABCB1 allows the NBDs to bind and hy-
drolyze ATP, while having the TMDs assume an outward-closed conformation.
This is in agreement with the expected conformational landscape sampled by
ABCB1 based on recent spectroscopic measurements and molecular dynam-
ics studies on mouse ABCB1 ([110]), where an outward-occluded state with
a closed NBD interface and outward closed TMD has been observed. Such a
conformation is also compatible with those observed in structures of related
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prokaryotic ABC exporters ([107], [113]), as well as the recently determined
ATP-bound zebrafish CFTR structure ([114]), and is expected to be generally
shared among various ABC exporter family members ([115]).
2.2.4 Details of the Zosuquidar-Binding Pocket
The zosuquidar-bound structure of ABCB1 reveals a large cavity that spans
almost the entire width of the lipid membrane (Figure 2D and Figure 3D and
E). The cavity is sealed from the external and cytoplasmic sides, and is lined
by residues from all 12 TMs of ABCB1 (Figure 2A and SI Appendix, Fig-
ure 6), comprising many of the residues identified in biochemical studies as
contributing to drug interactions of ABCB1 ([116], [117], [118], [119], [120],
[121]). Although some of these side chains have been observed to be in contact
with ligands in previously reported structures of ABCB1, these structures all
described inward-facing conformations, with no enclosed cavities observed and
fewer interactions with bound substrates ([93], [94], [96], [113]). As shown
in Figure 3D and E, our EM density unambiguously revealed two zosuquidar
molecules bound in the enclosed cavity, filling most, but not all of the available
space. As a consequence, residues from eight TMs directly interact with bound
zosuquidar. The two zosuquidar molecules assume defined orientations, are
wrapped around each other, and roughly follow a twofold rotational symme-
try. This is in stark contrast to structures of mouse ABCB1 in complex with
cyclic inhibitors in the inward-open conformation ([122]). The distribution
of interacting residues, which are fully conserved between our construct and
ABCB1H (green dots in Figure 2B and SI Appendix, Figure 6), demonstrates
that the two halves of ABCB1 contribute in a pseudosymmetrical fashion to zo-
suquidar binding, as the contacting residues belong to TM1, TM4, TM5, and
TM6 (first half of ABCB1) and to TM7, TM10, TM11, and TM12 (second
half of ABCB1). In addition to the many aromatic and hydrophobic residues,
there are polar or charged side chains in the observed cavity (SI Appendix,
Figure 10). The majority of these have been predicted to be part of the pri-
mary drug-binding site of ABCB1 ([94], [119], [120], [123]). Specifically, Y953
is seen in our structure to hydrogen-bond with one of the zosuquidar molecules
(SI Appendix, Figure 11B) as predicted based on molecular dynamics and mu-
tagenesis studies, although this study predicted only one zosuquidar bound
in the cavity in a different configuration compared with that observed in our
structure. The absence of interfering detergent, along with the close associa-
tion of the bound inhibitors with residues predicted to be primary contributors
to specific binding of zosuquidar ([116]), further validates the relevance of the
observed binding site. The observation of two bound zosuquidar molecules
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agrees with previous biochemical and structural findings suggesting that the
ABCB1 drug-binding pocket is capable of accommodating multiple ligands si-
multaneously ([122], [124]). The presence of many aromatic residues can offer
an adaptive plasticity to the pocket, in line with studies suggesting an induced
fit mechanism of ligand recognition ([125]). We conclude that ABCB1 may
bind inhibitors through a combination of specific interactions, leading to de-
fined binding modes and a rigid core of bound inhibitor molecules surrounded
by TM helices.
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Figure 3: Details of UIC2-binding interface and zosuquidar-binding pocket. (A)
Close-up view of the ABCB1-UIC2 interface with the UIC2-Fab-binding
region shown as an electrostatic surface potential map and ABCB1 shown
in ribbon representation. TM helices and ELs of ABCB1 are labeled.
ABCB1 residues interacting with UIC2-Fab or with a structural role in
stabilizing the outward-closed conformation of ABCB1 are shown as sticks
and labeled. (B) Similar view as in A, but with ABCB1 shown as semi-
transparent electrostatic surface potential map. UIC2-Fab is shown in
ribbon representation and colored blue (heavy chain) or red (light chain).
Select UIC2 residues within 5Å of ABCB1 are shown as sticks. (C) Se-
quence alignments of EL1, EL3, and EL4 regions of ABCB1H and mouse
ABCB1, with secondary structure motifs shown above the sequences.
Black dots represent residues of ABCB1H within 4Å of UIC2 as seen in
our ABCB1HM−X -UIC2 structure. (D) Ribbon diagram of ABCB1 viewed
parallel to the membrane plane, with several TM helices removed for clar-
ity. Two bound zosuquidar molecules are shown as pink and blue sticks,
and the corresponding EM density is shown as pink and blue mesh. Se-
lected ABCB1 residues within 4Å distance of bound zosuquidar are shown
as yellow sticks and labeled. (E) Similar to D but viewed from the external
side of the membrane.
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2.2.5 Conformational Changes Associated with NBD Closure
To understand the contributions of disulfide-mediated NBD trapping and zo-
suquidar binding to the TMD conformation and the formation of an inhibitor-
binding pocket, we determined two additional cryo-EM structures (Figure 4A).
The structure of an amphipol (A8-34) reconstituted, non-cross-linked variant,
ABCB1HM−EQ, was determined in the absence of any drugs or nucleotides, but
in complex with UIC2-Fab (SI Appendix, Figure 11). ABCB1HM−EQ harbors
an E → Q mutation in the Walker-B motif, which increases the stability and
limits the conformational heterogeneity of the sample. The ABCB1HM−EQ
structure revealed an inward-open conformation with wide NBD separation,
closely matching (rmsd = 1.88 for all aligned Cαatoms) previously reported
mouse ABCB1 structures ([94], [95], [97], [122]) (SI Appendix, Figure 11E).
A detailed structural analysis (Figure 4Fig. 3B) revealed that the transition
from the inward-open state to the disulfide-trapped, zosuquidar-occluded state
includes distinct changes in the TMDs, most significantly in the conforma-
tions of TM4 and TM10 (Figure 4C). Despite exhibiting different sequences
otherwise, the three residues P223, S238, and G251 in TM4 correspond to
identically spaced and located residues P866, S880, and G894 in TM10, al-
lowing for similar helix bending and kinking. Along with the already bent
and kinked TM6 and TM12, this amounts to four TM helices of ABCB1 that
form significant kinks, forming a cytoplasmic gate to the zosuquidar-binding
cavity and closing the lateral membrane opening that exists in the inward-
open conformation (Figure 5A and B). We then determined the structure of
disulfide-trapped ABCB1HM−X , also in complex with UIC2-Fab, but in the
absence of drugs or nucleotides. We found that the separation of the NBDs in
the apo ABCB1HM-X structure was identical to that of the zosuquidar-bound
state. The conformation of the external loops of ABCB1 and the confor-
mation of the interface with UIC2 binding are indistinguishable in the three
structures, which is in line with the observation that UIC2 binding allows the
transporter to cycle through its complete ATP hydrolysis cycle despite the
absence of a discrete outward-open conformation ([92], [112]). Although the
structure of disulfide-trapped apo ABCB1HM−X is at slightly lower resolution
than the zosuquidar-bound structure, side-chain density is still visible for most
TMs, allowing unambiguous determination of the side-chain register. When
all particles are used for 3D reconstruction, we observed blurred density in
the regions of TM4 (residues 237-244) and TM10 (residues 880-888) owing to
local conformational flexibility (SI Appendix, Figure 12, Figure 13, Figure 14).
Upon subclassifying, we could identify distinct and roughly equally populated
conformations where TM4 and TM10 either adopt kinked conformations (class
1/map 2) as observed in the zosuquidar-bound state (Figure 5C) or straight
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conformations (class 2/map 3) as observed in the apo-inward ABCB1HM struc-
ture. We conclude that the closing of the NBD gap by disulfide trapping,
which is transmitted to the TMDs via the coupling helices, allows TM4 and
TM10 to sample both the straight and kinked conformations. Upon binding
of zosuquidar, only the kinked conformation is observed. A stabilization of
the two TMDs of ABCB1 has been also been reported upon binding of the
third-generation ABCB1 inhibitor tarquidar ([117]), whose proposed binding
site overlaps with the zosuquidar-binding site in our structure, pointing to
similar modes of interaction with the transporter. In the related multidrug
transporter ABCC1/MRP1 ([126]), binding of substrate was accompanied by
a slight reduction in NBD separation and narrowing of the binding pocket,
which, nevertheless, remained open to the cytoplasm.
2.3 Conclusions
Our results provide a number of insights into the modulation of ABCB1, as well
as the chemistry of the underlying specific ligand interactions. First, we offer
visualization of a fully occluded ligand-binding cavity of a type 1 ABC trans-
porter occupied by a small-molecule inhibitor, identifying the details of zo-
suquidar binding to ABCB1. Such a conformation has been extremely difficult
to trap owing to the highly dynamic nature of ABCB1, prompting us to employ
covalent linkage of the NBDs. Given that disulfide-trapped ABCB1HM−X hy-
drolyzes ATP at a similar rate as the native protein and maintains stimulation
by zosuquidar, the observed conformation provides physiologically relevant in-
sight. This is further supported by the fact that we observed spontaneous and
near-complete cross-linking for the designed cysteine pairs, and our structural
analysis revealed the majority of particles to belong to a homogeneous class,
consistent with an occluded state of ABCB1. Visualization of an occluded
ABCB1 cavity offers a unique tool for in silico studies of drug binding to the
transporter, which have so far relied on inward-open structures of ABCB1 and
models based on different transporters. The ability of two inhibitor molecules
to bind in tandem raises the possibility of cooperativity in binding, which, in
the absence of a more sensitive readout for drug binding, we are currently un-
able to fully analyze. The zosuquidar-inhibited state captured in our structure
also raises the question of whether transport substrates can bind similarly in
well-defined orientations to the exact same site in ABCB1. Interestingly, based
largely on its opposing ATPase modulatory behavior in lipid- or detergent-
embedded ABCB1, zosuquidar, along with elacridar and tariquidar, has re-
cently been proposed to bind to a low-affinity site in the presence of detergent,
which is thought to bind to, and hence render, the proposed high-affinity site
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Figure 4: Conformational changes in ABCB1. (A) Comparison of apo-inward
ABCB1HMUIC2 (blue) and disulfide-trapped, apo ABCB1HM−X -UIC2
(yellow) using UIC2-Fab as an anchor point for the superposition. The
gray box represents the approximate location of the plasma membrane.
(B) Close-up view of the NBDs of the two structures shown in A, but us-
ing NBD1 as the superposition anchor. The coupling helices of ABCB1HM
and ABCB1HM−X are colored red and black, respectively. The Cα atoms
of V264 and V908 of the coupling helices are represented as spheres, with
the distance between them shown as black and red arrows. (C) Superposi-
tion of the TM helix pairs TM3-TM4 and TM9-TM10 of the two ABCB1
structures colored as in A. Red and green spheres depict Cα atoms of se-
lected residues, with numbers indicated. A sequence alignment of TM4
and TM10 of human ABCB1 is shown below the structures, and the des-
ignated residues are indicated with arrows.
inaccessible for the inhibitor ([103]). While we cannot categorically rule out
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such a different binding mode for zosuquidar, a number of observations help
further validate the physiological relevance and significance of our zosuquidar-
bound structure. First, we observe no interfering detergent molecules in the
binding cavity, arguing against detergent-mediated occlusion of the primary
zosuquidar-binding site. Second, our EC50 values for zosuquidar modulation
of LMNG-solubilized ABCB1 match those measured in native membranes,
with our observed modulation effect being much stronger than that reported
for DDM-based preparations ([103]). Third, the conformational changes in
TM4 and TM10, although never before seen to occur in tandem, closely match
those observed for TM4 in mouse ABCB1 in complex with select cyclic peptide
inhibitors ([122]). In light of these findings, the explanation for the opposing
effects of zosuquidar on ATPase activity of lipid-reconstituted or detergent-
solubilized ABCB1 may need to be readdressed.
Second, the ability to narrow the NBD gap by cross-linking rather than ad-
dition of nucleotides allowed for the intriguing finding of abrogated ATPase
stimulation by paclitaxel. While subtle conformational changes within the
observed occluded cavity upon full NBD closure with bound nucleotides are
possible, this result might indicate that some transport substrates (including
paclitaxel) cannot access the occluded conformation seen in our zosuquidar-
bound structure. Although individual instances of helix bending/kinking have
previously been observed in ABCB1 structures ([95], [122], [127]), our struc-
tures visualize simultaneous conformational changes in the two halves of the
transporter, involving conserved, helix-breaking residues. The structural rear-
rangements in the TMDs may not only occur during inhibition but possibly
also during a productive transport cycle.
Finally, we elucidate the conformational epitope of the UIC2 antibody and the
mechanism of its inhibitory activity. Most importantly, our structure clearly
rules out the existence of an outward-open ABCB1 conformation in the pres-
ence of UIC2 as speculated upon based on low-resolution EM analysis of human
ABCB1-UIC2 complexes ([92]).
Overall, the work presented herein opens new avenues for the development of
more potent antibody and small-molecule inhibitors of ABCB1 that could be
used alone or in combination with small-molecule inhibitors, while shedding
light on the conformational changes undergone by the transporter upon ligand
binding.
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Figure 5: Structural changes in the translocation pathway. (A) Surface represen-
tations of inward-open ABCB1HM and disulfide-trapped ABCB1HM−X
structures (without bound UIC2-Fab) colored blue and yellow, respec-
tively. Internal cavity volumes are depicted as dark blue and gold-colored
surfaces. The dashed oval indicates the location of the occluded TM cav-
ity that binds zosuquidar in the zosuquidar-bound structure. The gray
box represents the membrane. (B) Translocation pathways of ABCB1HM
and ABCB1HM−X colored as in A, but viewed from the cytoplasmic side
of the membrane. TM helices are shown as ribbons and numbered. Ar-
rows indicate the constriction point or cavity gate formed by kinks in
TM4 and TM10, closing off the cavity to the cytoplasm in the occluded
ABCB1HM−X structure. (C) Side views of ribbon representation of TM4
and TM10 and the corresponding EM density of ABCB1HM−X structures.
(Left and Center) Two populations of disulfide-trapped apo ABCB1HM−X ,
suggesting equilibrium between kinked (closed) and straight (open) con-
formations. (Right) Zosuquidar-bound structure, where only the kinked
conformation exists. Density for the bound zosuquidar molecules is shown
as red mesh.
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2.4 Materials and Methods
2.4.1 Protein Expression and Purification
A PCR-free cloning strategy was employed for all ABCB1HM constructs, which
were synthetically generated (Thermo Fisher Scientific). For the variant of
the ABCB1HM D-loop cross-link mutant (ABCB1HM−X), a 3C protease site
(LEVLFQGP) replaced residues 668-675 in the linker connecting the two halves
of the transporter. All genes were cloned into an expression vector harboring
the pXLG gene expression cassette in a pUC57 vector (GenScript) ([128], [129])
between BamH1 and Not1 restriction digestion sites. All genes were cloned
with a C-terminal EYFP/rho-ID4 tag with an intervening precision (3C) pro-
tease cleavage site between the protein and purification tag. A stable cell line
for ABCB1HM−X was generated using the Flp-In T-REx Kit (Thermo Fisher
Scientific) for inducible expression as per the manufacturer’s guidelines.
Transient expression for ABCB1HM and ABCB1H (sequence ID AAA59576.1)
constructs was carried out in HEK293T adherent cultures. Cells were grown
and maintained in DMEM (Thermo Fisher Scientific) supplemented with 10%
FBS (Thermo Fisher Scientific) at 37°C with 5% CO2 under humidified condi-
tions. Purified DNA was mixed with branched polyethylenimine (PEI; Sigma)
at a 1:2 (DNA/PEI) ratio and applied to cells after exchanging medium to
expression medium (DMEM + 2% FBS). Expression and growth media were
supplemented with a penicillin/streptomycin mixture (Thermo Fisher Scien-
tific). For ABCB1H , expression was allowed to proceed for 72 h at 37°C. All
synthetic gene constructs were expressed in the presence of 4mM valproic acid
(Sigma) at 30°C for 96h. A stable cell line for ABCB1HM−X was grown and
maintained similarly; induced with 1μg·mL−1 tetracycline and protein expres-
sion, it was allowed to proceed for 72h at 37°C. Cells were washed with PBS
before being harvested and flash-frozen in liquid nitrogen for storage at -80°C.
For protein purification, frozen cell pellets were thawed and homogenized using
a Dounce homogenizer in an eightfold (vol/wt) excess of resuspension buffer
containing 150mM NaCl and 25mM Hepes (pH 7.5), in addition to 10-20%
glycerol and a protease inhibitor mix (prepstatin A, leupeptin, soy trypsin in-
hibitor, and phenylmethylsulfonyl fluoride), followed by addition of detergent,
except for the ABCB1HM−EQ sample for EM analysis, which was purified in
250mM NaCl and 50mM Tris (pH 7.5). For all ABCB1H genes, protein extrac-
tion was allowed to proceed in the presence of a mixture of 0.4% dodecyl mal-
topyranoside (DDM), 0.1% octaethylene glycol monododecyl ether (C12E8),
and 0.1% CHS for 90min before being centrifuged for 30min at 37,060 × g in
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a SA600 fixed-angle rotor. For ABCB1HM constructs, 0.5/0.05% LMNG/CHS
was used for solubilizing protein for 60min before centrifugation. Clarified
supernatant was applied to Sepharose-coupled Rho-ID4 antibody (University
of British Columbia) and incubated for 3-18h. Beads were washed four times
with 10 column volumes (CV) of purification buffer containing 150mM NaCl,
25mM, and Hepes (pH 7.5), along with 10-20% glycerol and 0.01/0.01/0.004%
DDM/C12E8/CHS (ABCB1H) or 0.02/0.004% LMNG/CHS (all ABCB1HM
constructs). For the ABCB1HM−EQ sample for EM analysis, buffer and salt
components were adjusted to contain 250mM NaCl and 20mM Tris (pH 8.0).
For direct comparison of ABCB1H and ABCB1HM constructs in ATPase as-
says, DDM/C12E8/CHS-solubilized ABCB1H was bound to ID4 columns and
exchanged to LMNG/CHS buffer during the wash and subsequent purifica-
tion steps. Protein was eluted by adding 3 CV of wash buffer containing a
1:10 wt/wt excess of 3C protease or by addition of 0.5mg/mL ID4 peptide
(GenScript) for 2-18h. The 3C protease was His-tagged and removed by incu-
bating the cleaved protein with nickel nitrilotriacetic acid beads (Qiagen). All
purification steps were carried out at 4°C.
2.4.2 Antibody Purification and Fragmentation
UIC2 hybridoma cells were cultured in Wheaton CeLLine Bioreactors as per
the manufacturer’s recommendations. Protein G and Protein A (GenScript)
columns were used for antibody purification and antibody fragmentation, which
were carried out using the Fab Preparation Kit protocol (Thermo Fisher Sci-
entific). Fab purity was judged by SDS/PAGE, followed by size exclusion
chromatography (SEC), after desalting into storage buffer containing 150 mM
NaCl and 25 mM Hepes (pH 7.5) or 250mM NaCl and 20mM Tris (pH 8.0)
for use with ABCB1HM−EQ for EM analysis.
2.4.3 Cytotoxicity Assays
The ABCB1HM−X stable cell line was grown and maintained as described
above. Induced or noninduced cells were plated at a density of 5,000-10,000
cells per well of a 96-well plate and allowed to attach for 1-2h. Cells were
then exchanged to medium containing paclitaxel at various concentrations and
incubated for a further 48-72 h. Medium was exchanged, and cell viability was
measured using the WST-1 cell proliferation/viability kit (Sigma). The assay
was repeated in the presence of 10μM zosuquidar, added 1-3h before paclitaxel.
To test the effect of UIC2, induced cells were plated as described above and
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preincubated with varying UIC2 concentrations for 1h at 37°C. Paclitaxel was
then added directly to the medium (final concentration 0.5μM), cells were
incubated for 48-72h, and viability was measured described as above. The
results shown are for three independent experiments (Figure 2B and C and
SI Appendix, Figure 7A). Data were fit to a sigmoidal dose-response curve,
plotted in GraphPad Prism 6, and normalized to calculated Bmax values from
the fitted curve after subtraction of the calculated Bmin values (to adjust for
background levels in separate assays) from the respective datasets.
2.4.4 Cysteine Cross-Linking of ABCB1HM−X
Detergent-purified protein was incubated with 1 mM dichloro(1,10-phenanthroline)
copper(II) (Sigma) for1 h at 4°C and desalted back into buffer lacking the ox-
idant using Sephadex G-25 desalting columns (GE Healthcare) to stop the
reaction. For ABCB1HM−X−3C , cross-linking efficiency was analyzed by SD-
S/PAGE (SI Appendix, Figure 7B). The 3C protease-cleaved samples were
loaded in reducing and nonreducing loading buffer, and the ratio of cross-
linked to non-cross-linked transporter was judged by comparing the full trans-
porter band (cross-linked, ~140kDa) and the cleaved half-transporter bands
(non-cross-linked, ~50kDa). Cross-linked protein was subsequently used for
biochemical assays and EM sample preparation as described below.
2.4.5 ATPase Assays
Measurements of ATP hydrolysis were performed using a molybdate base col-
orimetric assay as previously described ([130]). Protein concentrations used
in the assays in the range of 0.1-0.2mg/mL zosuquidar (Medkoo Biosciences)
and taxol/paclitaxel (Sigma) were dissolved in DMSO and added to reaction
mixes at the desired concentrations. The reactions were started upon addition
of 2mM ATP in the presence of 10mM MgCl2 at 37°C. For Km determination,
a range of ATP concentrations was used. Linear regression and statistical
analyses were performed using GraphPad Prism 6.
2.4.6 Antibody-Binding Assay
Purified Avi-tagged proteins were first desalted into biotinylation buffer [75mM
NaCl, 25mM Hepes (pH 7.5), 10mM magnesium acetate, 10mM ATP, and
50μM biotin] containing the detergent/CHS mix used for protein purification
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before addition of 5-10μg biotin ligase BirA (produced in-house), and the reac-
tion was allowed to proceed overnight at 4°C, followed by desalting into buffer
containing 150mM NaCl,25 mM Hepes (pH 7.5), 10-20% glycerol (buffer A),
and the respective detergent/CHS mix. A total of 1-5 pmol of biotinylated pro-
teins was added to each well of a preblocked 96-well Neutravidin plate (Thermo
Fisher Scientific) for up to 1h at room temperature. All incubations were car-
ried out on a plate shaker (Unimax 1010 Orbital Platform shaker; Heidolph)
at 350rpm. Unbound transporters were discarded, and the wells were washed
three times with 200 μL of buffer A supplemented with the respective detergen-
t/CHS mix (buffer AD). A total of 100μL of serially diluted UIC2 antibody was
added to the wells and incubated for30 min at room temperature. Unbound
UIC2 was discarded, and the wells were washed three times with buffer AD
as before. Horseradish peroxidase (100μL)-conjugated goat mouse anti-IgG
(catalog no. A16072; Thermo Fisher Scientific) diluted to 1 mg/mL (1:1,500)
in buffer A was added to the wells for 30 min. After discarding unbound an-
tibodies, the wells were washed as before, followed by development using the
TMB Substrate Kit (Thermo Fisher Scientific). Absorbance (450nm) was read
using a BioTek Synergy HT plate reader. Readings were plotted against UIC2
concentrations and fit to a single-site specific binding equation in GraphPad
Prism 6. Data were normalized to calculated Bmax values for comparative
purposes.
2.4.7 EM Sample Preparation
LMNG/CHS-purified ABCB1HM constructs were mixed with a two- to three-
fold molar excess of UIC2-Fab. The ABCB1HM−EQ-UIC2 complex was mixed
with a 1:10 wt/wt excess of amphipol A8-35 (Anatrace) for 4h at 4°C, followed
by overnight biobead (BB-SM2)-mediated removal of detergent. UIC2-Fab
complexes of detergent-purified and amphipol-reconstituted samples were con-
centrated to 5-8mg/mL before being purified on a G4000SWXL SEC column
in buffer containing 250 mM NaCl and 20mM Tris (pH 8.0) (amphipol) or
150mM NaCl and 25mM Hepes (pH 7.5) (detergent samples). Peak fractions
corresponding to the purified complexes were pooled and used for cryo-EM grid
preparation. For the zosuquidar complex, the inhibitor was added to a final
concentration of 10μM before grid preparation. Freshly purified samples were
applied to glow-discharged Lacey carbon grids (LC200; Electron Microscopy
Sciences) and plunge-frozen in liquid nitrogen-cooled liquid ethane using a Vit-
robot Mark IV (FEI) operated at 4°C with a blotting time of 3-4s and >90%
humidity.
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2.4.8 Data Collection and Processing
An overall data processing scheme for structure determination is provided in SI
Appendix, Figure 14. Two different microscopes were used for data collection
for the detergent-purified, cross-linked samples and the amphipol-reconstituted
samples (FEI Titan Krios 1 and 2, respectively; SI Appendix, Figure 15).
Grids were clipped for loading into a Titan Krios microscope (FEI) running
at 300 kV equipped with a Gatan Quantum-LS Energy Filter (GIF) and a
Gatan K2 Summit direct electron detector. For the zosuquidar complex of
ABCB1HM−X-UIC2, image stacks comprising 48 frames were collected at a
nominal magnification of 165,000× in superresolution mode with an estimated
dose per frame of 1.54 electrons per square angstrom, corresponding to a to-
tal dose of 74 electrons per square angstrom. Stacks were motion-corrected,
dose-weighted, and twofold Fourier-cropped to a calibrated pixel size of 0.84Å
in MotionCor2 ([131]). Contrast transfer function (CTF) estimates were per-
formed using gCTF ([132]), followed by particle picking and extraction of a
total of 469,224 particles from 2,479 micrographs in Relion 2.0 ([133], [134],
[135]). After several rounds of 2D classification, 352,880 particles in all us-
able classes were used for 3D classification using a low-pass-filtered map of the
cross-linked apo structure (discussed below) as a reference. Of those, two near-
identically looking classes comprising 231,969 (66%) particles were combined
and used for 3D refinement and postprocessing to yield a 3D map at 3.78Å res-
olution, whereas the remaining particles fell into unusable classes with missing
NBDs. We suspect this arises from poorly averaged or heterogeneous particle
sets, as well as missing orientation views and the fact that despite high cross-
linking efficiency, a subset of transporters may not be linked, and may thus
add to overall variability in conformational mobility of the NBDs. A model
map for the detergent belt was generated from this map in UCSF Chimera
([136]), masked in Relion, and used for signal subtraction from the input set of
particles used for the initial refinement to yield a final postprocessed map res-
olution of 3.58Å. The reported resolution for all maps was based on the FSC
cutoff criterion of 0.143 ([137]). Local resolution estimation was performed
using ResMap ([138]).
For the apo ABCB1HM−X-UIC2 sample, image stacks comprising 80 frames
each with an estimated dose per frame of ~0.9 electrons per square angstrom,
corresponding to a total accumulated dose of 72 electrons per square angstrom,
were collected at a magnification of 105,000× in superresolution mode, followed
by motion correction and dose weighting in MotionCor2. Stacks were twofold
binned via Fourier-cropping to a calibrated pixel size of 1.387Å for processing
using Relion 2.0. CTF estimates were performed using gCTF, followed by
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picking and extraction of a total of 820,566 particles from 2,614 micrographs
in Relion. After 2D classification, an input set of 785,152 particles was used
for 3D classification using a low-pass-filtered map of the ABCB1HM−EQ-UIC2
structure (discussed below) as a reference. Of those, 517,053 particles (66%)
from two similar-looking 3D classes were combined for a round of 3D refine-
ment that yielded a 4.78Å map. After masking and postprocessing in Relion
using automatically determined B-factors, we obtained a resolution of 4.33Å.
This map was used to obtain a model map for the detergent belt, which was
generated as described for the zosuquidar complex dataset and used for sig-
nal subtraction using the input particle set used for the initial refinement.
The new signal-subtracted dataset was then used to refine a single 3D class
comprising 517,053 particles. Masking and postprocessing using automatically
determined B-factors as before yielded a final map with a resolution of 4.14Å
(map 1) that was used for model building. A second, smaller detergent belt
model was similarly generated to create a second signal-subtracted dataset
that served as input for one more round of 3D classification, where a search
for three 3D classes yielded two distinct classes that shared a similar archi-
tecture but showed differences in conformations of TM4 and TM10. Class
1 (153,652 particles) and class 2 (158,827 particles), containing kinked and
straight conformations of TM4 and TM10, respectively, were both refined to a
resolution of ~4.5Å (map 2 and map 3, respectively). The remaining particles
fell into the third class containing blurred density in the regions of TM4 and
TM10 and were not analyzed further.
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For the ABCB1HM−EQ-UIC2 complex, image stacks comprising 80 frames each
were collected at a nominal magnification of 105,000× in superresolution mode
with an estimated dose per frame of 1.0 electron per square angstrom, cor-
responding to a total dose of 80 electrons per square angstrom. The soft-
ware suite Focus ([139]) was used for online data processing and pruning,
applying motion correction with MotionCor2, including twofold binning of
the recorded micrographs after motion correction to a calibrated pixel size
of 1.336Å and CTF estimation with gCTF. Particles were picked with gAU-
TOMATCH ([140]) using a template-based approach, with templates created
from the published ABCB1-UIC2 complex structure ([108]) using e2proc2d.py
(EMAN2) ([141]). The same model was used later as a starting model in 3D
classification. Micrographs were imported for processing in Relion, and a total
of 347,049 particles were extracted from 2,038 micrographs, followed by two
rounds of 2D classification, to yield a particle set of 112,196 particles. Follow-
ing two rounds of 3D classification, the remaining 78,282 particles were used
for 3D auto-refinement in Relion. Partial signal subtraction was performed to
remove the amphipol belt for final 3D refinement and postprocessing to yield
a final resolution of 6.25Å.
2.4.9 Model Building and Refinement
Postprocessed maps, as well as non-B-factor sharpened maps were used for
model building in Coot ([142]) for all datasets. The quality of electron den-
sity in the TMD regions of the apo and zosuquidar maps allowed for de novo
model building. The map quality in the NBD region was, on average, of lower
quality compared with the TMDs, which were resolved to near-atomic reso-
lution (SI Appendix, Figure 9 and Figure 12). Modeling of the NBD region
was therefore guided by published structures of ABCB1 [Protein Data Bank
(PDB) ID codes 4M1M and 5KO2], followed by manual adjustment where re-
quired and permitted by map quality. The UIC2 crystal structure (PDB ID
code 5JUE) was manually docked into the Fab density using UCSF Chimera,
followed by adjustment in Coot. Two molecules of zosuquidar were unam-
biguously fit into the corresponding electron density in the ABCB1-binding
pocket. We observed electron density characteristic for a bound phospholipid
that was tentatively modeled as phosphatidylethanolamine (PE) in both the
apo- and zosuquidar-bound occluded ABCB1HM−X structures. PE and glycan
monomers were obtained from the Coot monomer library (monomer codes 3PE
and NAG, respectively). Geometric restraints for all ligands were generated in
Phenix. The model for ABCB1HM−EQ-UIC2 was based on the structure of the
apo-occluded state. Map quality allowed for rebuilding the TMDs to fit the
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density and was guided, in part, by the structure of mouse ABCB1 (4M1M).
Real-space refinement of the models was carried out in Phenix ([143], [144]),
with default restraint parameterization along and automatically generated sec-
ondary structure restraints. Refinement statistics for all models are presented
in SI Appendix, Table S1. For validation of the zosuquidar complex model,
random coordinate errors up to 0.3Å were introduced into the refined model,
which was subsequently refined against one of the half-maps from the 3D auto-
refine run from Relion. Minimal differences in FSCs computed between the
refined model and the half-map used for refinement compared with those be-
tween the refined model and the half-map excluded from refinement point to
a model free from overrefinement (SI Appendix, Figure 8). All figures were
prepared using UCSF Chimera and PyMOL (The PyMOL Molecular Graphics
System, Version 1.8; Schrödinger, LLC). Cavity volumes were calculated using
HOLLOW ([145]) as described. Structure alignment and rmsd calculations
were done in PyMOL. Ligand interaction diagrams were prepared in LigPlot+
([146]). Residue numbers in figures are based on equivalent residues in the
fully human protein.
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Figure 7: Functional characterization and disulfide trapping of ABCB1. A Cell vi-
ability analysis of ABCB1HM−X stable cell line in the presence or ab-
sence of tetracycline induction (n=3, error bars indicate s.d).). B SDS-
PAGE of ABCB1HM−X−3C harboring a protease cleavage site for deter-
mining disulfide cross-linking efficiency. Cross linked species (+) and
non-cross linked species (−) are shown along with bands corresponding
to ABCB1HM are shown for comparative purposes (C). M represents
the molecular marker sample. C ELISA-based UIC2 binding analysis
of ABCB1H , ABCB1HM . disulfide- trapped (ox) or DTT-reduced (red)
ABCB1HM−X . (n=3, error bars represent s.d). D Basal and zosuquidar
(10μM) or Paclitaxel (10μM) stimulated ATPase rates for ABCB1HM ,
disulfide cross-linked ABCB1HM−X . Also shown are ATPase rates for
DTT-reduced ABCB1HM−X in the presence of zosuquidar or Paclitaxel
(n=3, error bars represent s.d). E Zosuquidar-stimulated ATPase rates of
ABCB1HM , ABCB1H , and disulfide-trapped (ox) or DTT-reduced (red)
ABCB1HM−X (n=3, error bars indicate s.d). F Comparison of EC50 val-
ues for zosuquidar modulation of ATPase activity for detergent purified
and oxidized or reduced ABCB1HM−X and ABCB1HM (n=3, error bars
represent s.d). EC50 values were in the range of 0.2-0.25μM for all three
samples.
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Figure 6: Sequence alignment of human ABCB1 (ABCB1H) and the chimeric
human-mouse ABCB1 construst (ABCB1HM ), with secondary structure
assignment of transmembrane helices (TM) and coupling helices (CH)
shown and numbered. Black dots indicate residues of the drug binding
pocket (5Å distance to bound zosuquidar) whereas red dots indicate the
subset of these within 4Å of either of the two zosuquidar molecules seen
in the zosuquidar-bound ABCB1HM−X -UIC2 structure.
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Figure 8: Cryo-EM analysis of zosuquidar-bound, disulfide-trapped ABCB1HM−X -
UIC2 complex. A Representative micrograph at -2.6μm defocus along with
representative 2D classes. Scale bar is indicated in white. B Front and back
views of cryo-EM volume colored according to local resolution estimate.
The color key s shown on the right, numbers indicate Å resolution. C FSC
curves showing resolution estimates determined by 0.143 and 0.5 cutoff
criterion (black and grey dashed lines, respectively). D Model vs map FSC
curves for a model refined against half map 1. The FSC curve calculated
against half map 1 (work) are shown in black while that against half map
2 (test) is shown in blue.
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Figure 9: Quality of EM density (blue mesh) of the structure of disulfide-trapped,
zosuquidar-bound ABCB1HM−X -UIC2. Top, pairs of transmembrane do-
mains are shown as ribbons (yellow), with selected side chains shown as
sticks. Bottom, NBDs and UIC2-Fab are shown as ribbons, zosuquidar
molecules are shown as sticks. The disulfide cross-linked cysteine residues
in the D-loops of the NBDs are shown as black sticks.
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Figure 10: Residue interactions of individual zosuquidar molecules (ball and stick
representation, colored similarly to Figure 7D-E) observed in the
ABCB1HM−X binding pocket. Residues interacting with both molecules
are indicated (red circle). Non bonded interactions are represented by
spoked arcs and hydrogen bonds are indicated by dashed black lines. A
Ligand interactions of zosuquidar molecule 1. B Ligand interactions of
zosuquidar molecule 2. ABCB1 residue Y953 is shown iine format.
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Figure 11: Cryo-EM analysis of ABCB1HM -UIC2. A Size exclusion purification
of amphipol-reconstituted ABCB1HM -UIC2 complex, with arrow show-
ing peak fraction used for grid preparation. B Representative micro-
graph with scale bar shown in white. C FSC curves of ABCB1HM -
UIC2 showing resolution estimate determined by 0.143 cutoff criterion
(dashed lines). D Overall structure of ABCB1HM -UIC2 complex show-
ing inward-open ABCB1HM (cyan ribbon) in complex with UIC2-Fab,
whose heavy and light chains are colored red and orange, respectively.
The EM density is shown as a transparent surface. E Superposition of
inward open ABCB1HM (from our UIC2 complex structure) and mouse
ABCB1 (ABCB1M ) (r.m.s.d for all aligned atoms = 1.88Å)
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Figure 12: Cryo-EM analysis of disulfide-trapped apo ABCB1HM−X -UIC2. A Size
exclusion purification of detergent-purified ABCB1HM−EQ-UIC2 com-
plex with arrow showing peak fraction used for grid preparation. B
Representative micrograph of cross-linked ABCB1HM−X -UIC2 at -2.5μm
defocus along with representative 2D classes. The scale bar is indicated in
white. C FSC curves showing resolutions estimate determined by 0.143
and 0.5 cutoff criterion (black and grey dashed lines, respectively). D
front and back views of cryo-EM volume colored according to local res-
olution estimate. The color key is shown on the right, numbers indicate
Å resolution.
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Figure 13: Quality of EM density (blue mesh) of the structure of disulfide-trapped
apo ABCB1HM−X -UIC2. Top, pairs of transmembrane domains are
shown as ribbons (yellow), with selected side chains shown as sticks. Bot-
tom, NBDs and UIC2-Fab are shown as ribbons. The introduced cysteine
residues in both NBD D-loops are shown as black sticks.
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Figure 14: Pipeline of EM data processing and 3D classification for all datasets in-
cluded in manuscript. Numbers in red starting set of all picked particles.
3D classification steps are boxed (dashed lines) and include the percent-
age of particles in each class indicated below the respective 3D classes.
Final post processed maps are boxed (solid lines) with final number of
particles and map resolution (blue text) indicated below each. −DB and
−AB refer to subtraction of the detergent and amphipol belts, respec-
tively.
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Figure 15: Summary of Cryo-EM data and model parameters.
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3 Bile Salt Export Pump (BSEP)
T he bile salt export pump (BSEP) belongs to the ATP binding cassette(ABC) superfamily. It is expressed in hepatocytes and is localized at the
canalicular apical side. BSEP is the only transporter for conjugated mono-
valent bile salts into the bile. Bile salts facilitate digestion and absorption of
dietary fat by formation of micelles with lipids. Inhibition of BSEP leads to
reduced bile flow. This can cause accumulation of bile salts in the liver to a
cytotoxic level. Thereby, BSEP deficiency can cause various genetic forms of
cholestasis, such as progressive familial intrahepatic cholestasis type 2 (PFIC2),
benign recurrent intrahepatic cholestasis type 2 (BRIC2) and drug-induced
liver damage (DILI). To date, about 200 missense mutations in ABCB11, the
gene encoding BSEP, have been reported. However, the phenotype-genotype
correlation has not been clarified. In this work we present the first three struc-
ture based models of BSEP. BSEP bound to glibenclamide, a drug inhibiting
BSEP function, and two structures in presence of substrate, describing dif-
ferent steps of the transport cycle. Potential models of the transport cycle
are outlined in context of those models. Selected point mutations involved
in disease conditions are pointed out and explained in context of the model.
Despite the high sequence identity between BSEP and Pgp, these transporters
show significantly different substrate specificity. While Pgp transport a host
of substrates, BSEP transport is limited to monovalent conjugated bile salts.
We show the presence of a loop reaching in the cavity on the cytosolic side.
This could be an explanation for the strict selectivity of BSEP.
Contents
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.4 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
3.5 Considerations for Pgp Based on BSEP Results . . . . . 70
3.1 Introduction
3.1.1 Enterohepatic Cycle: Release and Recovery of Bile Salts
Bile is a secretion produced by the liver. Its major components are water, con-
jugated bile salts and phospholipids. Further components are electrolytes,
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cholesterol, alkaline phosphatase, lecithin, and metabolic products ([147]).
Hepatocytes excrete bile components to the canaliculi, from where the bile
flows to the gall bladder ([148]). Contraction of the gall bladder and subse-
quent bile flow to the duodenum is triggered by cholecystokinin, a peptide
hormone acting on the smooth muscle cell of the gall bladder ([149]). Release
of cholecystokinin is controlled by specialized cells in the duodenum, capable
to perceive the presence of dietary fat. In the duodenum conjugated bile salts
help to emulsify lipids. This increases the surface area for pancreatic lipases
to break down dietary fat. The alkaline pH of bile neutralizes the acidic pH of
the chyme and activates pancreatic lipases. Bile salts form mixed micelles with
free fatty acids and fat-soluble vitamins. This is crucial for effective resorption
in the duodenum and jejunum. The majority of bile salts are resorbed in the
ileum the most distal segment of the thin intestine. Bile salt resorption is
accomplished by the apical sodium-dependent bile acid cotransporter (ASBT)
in an active process using the sodium gradient as driving force. Subsequently
the heteromeric organic solute transporter (OSTα–OSTβ) transports the bile
salts over the basolateral membrane into the blood stream ([150]). The hepatic
portal system carries bile salts directly back to the liver. Sodium-taurocholate
cotransorting polypeptide (NTCP) mediates uptake of bile salts into hepato-
cytes from where they are secreted over the canalicular membrane by the bile
salt export pump (BSEP) ([151]). The circulation of bile salts and other sub-
stances from the liver into bile, followed by resorption in the small intestine
and transport to the liver over the portal circulation is called enterohepatic
circulation. This process is important for the recovery of bile salts, as a grown
up person has a pool of bile salts of only 2-4 gram. This pool cycles several
times a day to ensure a efficient uptake of fat from chyme. Daily up to 30 gram
of bile salt are secreted to the gall bladder and reabsorbed ([148]). However
only 0.5 grams are lost, what implies a recovery rate above 90% ([152]).
3.1.2 What Are Bile Salts?
Bile salts belong to the class of steroids. As such they contain 3 cyclohexane
and a cyclopentyl ring. By IUPAC conventions the cyclohexane rings are
labeled ring A, B, C and the cyclepentyl ring is labeled D. Hydroxygroups at
C3, C7 and C12 render bile salts more polar than cholesterols. These hydroxyl
groups point to the concave side adapted by the ring structure, whereas the
methyl groups at positions 18 and 19 point to the convex side (Figure 16). This
renders the concave side hydrophilic and the convex side lipophilic, causing
surfactant properties of bile salts ([153]). The primary bile salts cholic acid
and chenodeoxycholic acid are synthesized from cholesterol. At physiological
pH the carboxyl group is ionized. Therefore bile acid and bile salt are the same
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Figure 16: Chemical structure of cholic acid on the left, with labeled positions of
hydroxy groups, cyclohexane, and cyclopentane rings. On the right a
schematic drawing indicates the orientation of hydrophilic groups in 3D.
([154])
in a physiological context. For simplification we refer to them as bile salts.
Conjugated bile salts consist of primary bile salt linked to glycine or taurine
by an amide bond. Secondary bile salts are the result of bacterial modifications
on conjugated bile salts in the colon. A fraction of bile salt not resorbed in
the small intestine is modified by colonic microbiota and then recovered in
the colon by passive absorption. Conjugation of bile salts decreases the pKa
of a primary bile salt. This enhances the emulsifying capacity. Bile salts
are essential for efficient uptake of dietary fat and fat-soluble vitamins. The
surfactant property of bile salts emulsifies dietary fat to increase the surface
for enzymatic digest. Mixed micelles of bile salts and lipophilic substances
assist uptake of these lipophilic compounds. In addition bile salts are the
major way for disposal of cholesterol in humans. This is important as humans
lack the enzyme to catabolize sterols. On one hand loss of not resorbed bile
salts is compensated by synthesis of bile salts from cholesterol. On the other
hand cholesterol is also secreted BSEP independent into bile. In this case bile
salts keep cholesterol soluble to prevent formation of gallstones. Due to their
antimicrobial activity, mostly on gram-positive bacteria, bile salts regulate the
bacterial growth and microbial composition in the gut. At higher concentration
bile salts are cytotoxic. Therefore secretion to the gall bladder and formation
of mixed micelles are required to protect hepatocytes. ([154], ([155])
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3.1.3 Bile Salt Synthesis
Despite the high recovery rate of bile salts from the intestine, humans loose
about 0.5 gram of bile salt per day. To keep the pool of available bile salts
constant, new primary bile salt has to be synthesized de novo. This process
takes place in hepatocytes. Starting product for the synthesis is cholesterol,
which is transformed in several steps to cholyl-CoA or chenodeoxycholyl-CoA.
The hydroxylation at position 7 by cholesterol 7α-hydroxylase is the first and
rate-limiting step of this pathway. At the third step the pathway bifurcates and
7α-Hydroxy-4-cholesten-3-one can either react with 7α-hydroxy-4-cholesten-3-
one 12α-monooxygenase to build cholyl-CoA as a final product or it can react
with sterol 12α-hydroxylase to follow the pathway leading to chenodeoxycholyl-
CoA. The ratio of chenodeoxycholate and cholate is regulated by the activity
of sterol 12α-hydroxylase. In addition, alternative pathways exist to build
chenodeoxycholyl-CoA from cholesterol. As last step bile acid-CoA:amino acid
N-acyltransferase conjugates primary bile salts by the formation of an amide
bond between the primary bile salt carboxyl group and the amine of a glycine
or taurine. This leads to the 4 major conjugated bile salts glycocholic acid,
taurocholic acid, glycochenodeoxycholic acid and taurochenodeoxycholic acid.
De novo synthesis of bile salts is a complicated and slow process. Therefore
this process cannot compensate for impaired recovery of bile salts in the ileum.
([154], ([155])
3.1.4 BSEP and Secretion of Bile Salts into Bile
The bile salt export pump (BSEP) is an ATP dependent bile salt transporter in
the canalicular membrane. It belongs to the ATP-binding cassette transporter
family, in particular to the MDR/TAP subfamily. Context dependent it can be
named BSEP, ABCB11 or sister of P-glycoprotein (s-Pgp). The name s-Pgp
refers to the high sequence identity of BSEP to Pgp found, when it was identi-
fied at the canalicular membrane the first time. Sequence alignment of BSEP
indicates a high similarity of the N- and C-terminal half. Alignments and
secondary structure prediction propose that BSEP forms a pseudo-symmetric
full transporter with six transmembrane helices and a nucleotide binding do-
main (NBD) followed by another six transmembrane helices and a second NBD
([156]). According to sequence alignments NBD1 should be able to bind ATP,
but incapable of hydrolyzing it due to a degeneration in the walker B motif,
where M584 replaces the catalytically crucial glutamate. BSEP is presumed
to be the rate limiting step in hepatocellular bile salt secretion. Compared
to Pgp, BSEP has a very large extracellular loop between transmembrane do-
main 1 (TMD1) and TMD2. On this loop four potential N-linked glycosylation
sites are identified. The four sites N109, N116, N122 and N125 were shown to
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be glycosylated in a biochemical approach. Removal of glycans decreases the
biochemical half-life and thereby reduces the measured transport activity of
BSEP. While mutants of N109 and N116 still target the apical plasma mem-
brane, mutation of an additional glycosylation site leads to retention of BSEP
([157]). Substrates for transport by BSEP are conjugated bile salts. Primary
bile salts and cholesterol are not or not efficiently transported by BSEP. For
cholesterol other transporters in the canalicular membrane account for. The
transport path of bile salts across hepatocytes to the canalicular membrane is
not fully understood yet. However, multiple proteins are known to bind bile
salts and to potentially shuttle them through the cell for secretion by BSEP
such as 3α-hydroxysteroid dehydrogenase (3α-HSD), glutathione-S-transferase
(GST) and fatty acid binding protein (FABP) ([158], [159]).
3.1.5 Other Transporters of The Canalicular Membrane
At the canalicular membrane of hepatocytes many transporters work side by
side. Some of them have a very broad range of substrate, whereas others
are rather specific. Aside from BSEP we find ABCB1, ABCB4, ABCC2, and
ABCG5/ABCG8. These are the principal transporters at the canalicular mem-
brane ([152]).
ABCB1 is a transporter for xenobiotics. It has a broad range of substrates.
Intriguingly ABCB1 shares a very high sequence identity with BSEP of
51%. Therefore substrates for ABCB1 can easily show affinity for BSEP
and act as inhibitor. More details for ABCB1 can be found in Chapter 2.
ABCB4 is a phospholipid transporter, selective for phosphatidylcholine. Mal-
function of ABCB4 causes progressive familial intrahepatic cholestasis
type 3 (PFIC3). Phospholipids transported by ABCB4 over the canalic-
ular membrane form mixed micelles with bile salts, reducing bile salt tox-
icity. This is important to protect cholangiocytes and cholecystocytes,
the epithelial cells in the bile duct and gall bladder. ([160])
ABCC2 is also known as canalicular multispecific organic anion transporter 1.
It has a very wide substrate range and excretes numerous organic anions
including bilirubin conjugates from the cytoplasm across the canalicular
membrane. Apparently it can cotransport uncharged compound with
glutathione. ([161]).
Sterolin: The heterodimer of ABCG5 and ABCG8 forms the sterol pump
sterolin. Apparently other sterols than cholesterol can be excreted too.
Excretion of cholesterol and bile salts has to be in balance. Otherwise
cholesterol precipitates and forms gallstones. ([162])
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3.1.6 Diseases Associated With Mutations in BSEP
Cholestasis is a condition where bile flow is strongly reduced or completely
abolished. The most common cause for cholestasis are gallstones blocking the
bile duct. This type is called obstructive cholestasis. In case of a metabolic
type of cholestasis, bile formation in the liver is impaired. This condition
can be caused by mutations in transporters involved in bile formation or by
interference with those transporters. This type is often referred to as intrahep-
atic cholestasis. To date two diseases are connected to mutations in the gene
Abcb11 coding for BSEP ([152]). ([163])
BRIC: Benign recurrent intrahepatic cholestasis (BRIC) type 2 is a benign
disease caused by mutations in Abcb11. Episodes of cholestasis from
weeks to months are followed by episodes without symptoms for weeks
or years. The first episode of cholestasis takes places in the second or
third decade of a patients live. Symptoms for BRIC episode are itchiness
(pruritus), yellowing of skin and eyes (jaundice), discomfort, nausea, lack
of appetite, excess fat in feces and in long-lasting episodes of cholestasis
a shortage of fat soluble vitamins. BRIC can be induced by mutations
in various genes; type 2 is caused by a deficiency of BSEP. Normally
patients can regenerate during symptom free episodes and do not develop
a progressive disease. ([164])
PFIC: Progressive familial intrahepatic cholestasis (PFIC) type 2 is the severe
form of cholestasis triggered by BSEP malfunction. In contrary to BRIC
the symptoms show up within the first ten years of life. In some cases
cholestasis manifests in the very first year of a patients life. The disease
develops progressively and leads to liver disease and finally liver failure.
In patients with PFIC type 2 liver failure develops within the first few
years of life. It is assumed that liver failure is induced by bile salt ac-
cumulation in hepatocytes. Especially on mitochondria bile salts show a
toxic effect.
BRIC and PFIC can be considered to be part of a spectrum of intrahepatic
cholestasis disorders of varying severity. In BRIC type 2 bile salt transport is
impaired, whereas in PFIC type 2 transport is abolished. This can be caused
by changes in BSEP activity or by an impaired trafficking of BSEP in the cell,
reducing abundance of the transporter at the canalicular membrane. While
PFIC, including all types, is very rare with 1 case in 50’000 to 100’000 people,
BRIC is even less frequent. ([165])
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3.1.7 Interactions of Drugs With BSEP and Triggered Cholestasis
Apart from mutation derived BRIC and PFIC conditions, there are cases of
intrahepatic cholestasis triggered by drugs ([166]). A variety of drugs have
been found to be able to block BSEP as adverse effect. This can lead to
drug induced liver injury. Drugs as cyclosporin A, rifampicin, bosentan, and
glibenclamide have been shown to be competitive inhibitors of BSEP ([167].
Furthermore bosentan has been shown to increased the plasma level of bile
salts in a reversible way, accompanied by transaminase elevations in blood
plasma, a marker for liver injury ([168]). While detecting the inhibitory action
on BSEP is straightforward for some drugs, it can be more complicated in
other cases. Ethinylestradiol shows no sign of BSEP inhibition in some test.
Only if BSEP is coexpressed with MRP2 an inhibition can be detected. Appar-
ently MRP2 transports ethinylestradiol over the canalicular membrane. Solely
from the luminal side ethinylestradiol can inhibit transportation of conjugated
cholates ([167], [169]). Drug induced cholestasis is clinically relevant, but still
rather rare. There are indications for genetic risk factors for drug induced
cholestasis. Two single nucleotide polymorphisms (SNPs) associated with drug
induced cholestasis are c.1331T>C (p.V444A) and c.2029A>G (p.M677V).
These variants have the same transport activity, but lead to a lower abun-
dance of BSEP at the canalicular membrane. This is a possible explanation
for a higher susceptibility for drug induced cholestasis in the genetic back-
ground of SNP c.1331T>C and c.2029A>G. ([170])
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3.2 Results
This work on BSEP is an ongoing project in collaboration with Lancien Loïck
and Kaspar Locher at ETH Zürich. Expression and purification of BSEP as
well as functional assays are performed by Lancien Loïck. Because results of
this project are not published yet, Loïcks data are not shown here. Results are
restrained to following four structures obtained from three different samples.
BSEP_glibenclamide represents wild type BSEP inhibited by the antidiabetic
drug glibenclamide. BSEPeqATP is inactivated by a glutamate to glutamine
(EQ) mutation in the walker B motive. This mutation still allows binding, but
disables hydrolysis of ATP. BSEPeqATP_closed and BSEPeqATP_CL repre-
sent two different structures, derived from independent purifications of BSEP
harboring an EQ mutation in presence of ATP and taurocholate. All samples
are prepared in HEK cells and purified in n-Decyl-β-D-Maltopyranoside.
My contribution to this work comprised data collection, processing, model
building, and interpretation as written in this chapter.
3.2.1 Data Collection, Processings, and Model Building
All datasets were collected as image stacks comprising 50 frames at a nominal
magnification of 165,000× in super-resolution mode with an estimated dose
per frame of 2-2.5 electron per square angstrom, corresponding to a total dose
of 100-125 electrons per square angstrom. The software suite Focus ([139])
was used for data pruning and preprocessing, applying twofold binning of the
recorded micrographs to a calibrated pixel size of 0.831Å, motion correction
with MotionCor2 [131] and CTF estimation with CTFFIND4. Particles were
picked with gAUTOMATCH ([140]) initially without template, followed by a
template-based approach. Templates were created from the initial reconstruc-
tion using e2proc2d.py (EMAN2) ([141]). Therefore Relion 3D initial model
was used to generate a starting model. Micrographs were exported to scicore
for processing in Relion. For BSEP in presence of the inhibitor glibenclamide
(BSEP_glib) a total of 579,628 particles were extracted using a box size of
250px from 11,589 micrographs, followed by three rounds of 2D classification,
to yield a particle set of 390,372 particles. After one round of 3D classification,
the remaining 179,782 particles from the major of four classes were used for
3D auto-refinement and postprocessing. Relion postprocess reported an esti-
mated resolution of 3.7Å. For processing Relion version 2.0.4 was used. Due to
a bug affecting this version, the resolution of 3.7Å cannot be claimed as gold
standard resolution. Processing was repeated with a fixed version of Relion
(2.1b1), resulting in a resolution of 4.1Å. The map generated by the bugged
version shows only light signs of overfitting mostly in the worse resolved NBDs
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Figure 17: Pipeline of EM data processing for the datasets of BSEP in presence of
glibenclamide (BSEP_glib) and BSEP with an glutamate to glutamine
mutation in presence of MgATP and taurocholate adopting a seemingly
open conformation (BSEPeqATP_CL). Arrows indicate which classes
were used in the subsequent step.
and is in good agreement with the map from Relion 2.1b1. Therefore model
building was performed on the initial map, which showed significantly more
details consistent with sidechains of the model and a clear helical pitch. For
all other datasets the fixed version of Relion was used only.
For the map of BSEPeqATP_CL 826,072 particles were picked from 3941
micrographs. Most of those were actually not particles of BSEP, but detergent
micelles. Two rounds of 2D classification could remove most micelles, reducing
the particle set to 478,758 particles. In 3D classification remaining micelles
and broken particles were removed. A set of 183,457 particles from the best
class could finally be refined to a resolution of 4.8Å. For extraction a box size of
384px was used for all samples except for BSEP_glib. For speed improvements
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particles were binned 3× for classification runs. Figure 17 shows an overall
scheme for data processing of BSEP_glib and BSEPeqATP_CL.
For BSEPeqATP_closed 3504 micrographs were recorded. An initial set of
253,677 particles was reduced to 125,043 in a singe round of 2D classification.
Subsequent 3D classification with three classes led to a major class in closed
conformation. 73,121 particles from this class could be refined and postpro-
cessed to a resolution of 5.1Å.
Micrographs of BSEPeqATP showed a very low concentration of particles, but
many micelles. In order to miss no particle all micelles and particles were
boxed. As 2D classification did not work well due to the high number of mi-
celles in the particle set and due to the proximity of micelles to boxed BSEL
particles, only ice contaminations and boxes on the carbon edge were removed
by 2D classification. This reduced the set of 978,783 particles from 3754 mi-
crographs to 813,720 particles. 3D classification using a low-pass filtered map
of BSEP_glib with a mask successfully separated real BSEP particles from de-
tergent micelles. Remaining 94,452 particles were sent to another round of 3D
classification using four classes. Particles of the two major open classes were
combined and refined. The resolution of the postprocessed map reached 7.3Å.
Figure 18 shows an overall data processing scheme for BSEPeqATP_closed
and BSEPeqATP.
For model building a model of Pgp (pdb:3g5u) was morphed into the map
of BSEP_glib, using iMODfit ([171]). The morphed model was then used to
trace the chain. Transmembrane domains and loops could be build manually
de-novo in Coot [142]. For NBDs the domains of our ABCB1 model (pdb:6fn1)
were fitted using iMODfit, followed by a local refinement. The model was then
refined in phenix [144] followed by manual corrections. Molprobity reported
an all-atom clashscore of 6.4%, ramachandran plot outliers of only 0.67% and
90,4% in favored region. Phenix was used to convert the refined map into
MTZ format to allow in-situ adjustments of B-factor sharpening. For other
maps the model build in BSEP_glib was morphed into position by iMODfit,
and refined in phenix and manually in Coot.
3.2.2 Structure of BSEP Bound to Glibenclamide
The structure of BSEP in complex with glibenclamide was solved at a gold-
standard resolution of 4.1Å. Particles of this sample adapted a wide range of
conformations from wide open to rather closed. The classification of different
conformations was therefore not possible. The best resolution could be ob-
tained with all particles refined together in one class. The map of BSEP with
glibenclamide displays a inward open conformation. A total of 12 transmem-
brane domains (TMDs) build two bundles. Bundle A comprises H1,2,3,6,10,11,
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Figure 18: Pipeline of EM data processing for the datasets of BSEP with an glu-
tamate to glutamine mutation in presence of MgATP and taurocholate
adopting a closed conformation and (BSEPeqATP_closed) and the same
construct in the absence of taurocholate (BSEPeqATP). Arrows indicate
which classes were used in the subsequent step.
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whereas H4,5,7,8,9,12 build bundle B. The two bundles are opened to the cy-
tosolic side by an opening angle of 37°. The resolution in transmembrane
domains allowed an unambiguous placement of the polypeptide chain. Loops
were more difficult to fit, but could be build de novo after all. Due to the
flexibility of BSEP, nucleotide-binding domains (NBDs) could not be build de
novo. NBDs from ABCB1 model (PDB:6fn1) were fitted individually to the
densities and refined locally. The connection between H1 and H2 adapts a
beta-turn-beta-loop structure. This motif is a new feature not found in re-
lated ABCB transporters so far. The subsequent helix 2 shows less side chain
densities, probably due to an increased flexibility, based on the loop. At a low
threshold densities for two glycosylations can be observed. One glycosylation
site collocates with N109. A second glycosylation is detected for N116. No
densities were observable for potential glycosylation sites N122 and N125, but
N125 makes a contact to E96 on helix 1 instead. In the most extracellular
region of the cavity formed by BSEP an additional density is observable. A
single molecule of glibenclamide can be fitted in this density. Despite the lim-
ited resolution, the orientation of glibenclamide is unambiguous. Coordination
of glibenclamide by sidechains of H1 (F83), H2 (Y145), H6 (V368 and L364),
H7 (Y772, F776), H11 (N996 and Y1000), and H12 (F1018) is consistent. Ad-
ditional densities in the cavity close to glibenclamide are observable, but not
part of the drug not the protein. As expected no further densities matching
ATP of taurocholate were detected. For simplicity we refer to this model as
BSEL_glib.
3.2.3 Structure of BSEPEQATP with Taurocholate
BSEP with an E to Q point mutation in the Walker B motif adapted 2 different
conformations in presence of MgATP. Particles of one sample preparation led
to a map in closed conformation (BSEPEQATP_closed). This dataset could
be refined to an overall resolution of 5.1Å. Bundle A and bundle B have a
opening angle of only 20°. The model shows no access to the internal cavity,
neither from the internal, nor from the external site. From bundle A only H10
has missing densities, whereas from bundle B all helices have missing densities,
especially in the external facing TMS portion. Despite sample preparation in
presence of taurocholate and ATP, no additional density for taurocholate could
be found in the map. Two ATP molecules can be placed in the NBD densities,
using the outward facing map of ABCB1 (PDB:6c0v) as template. Domains
interacting with glibenclamide in the inhibitor bound map are packed very
tightly but interact only sparsely with each other. Encountered contacts are
Y145 with N996, Y83 with F1018, and Y772 with M805.
Particles from the other sample preparation gave rise to a map of BSEP in a
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Figure 19: Resolution estimation of BSEP_glib after refinement with Relion2.0.4
on top and Relion2.1b1 on bottom. Due to a bug in versions 2.0.4 the
reported resolution does not fulfill gold standard. Owing to additional
details the higher resolution map was used for model building, though
the lower resolution estimate has to be claimed. FSC curves on the left
indicate resolution estimate determined by 0.143 cutoff criterion. The
volume on the right shows local resolution estimated in Relion.
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Figure 20: On the left the difference density accounting for glibenclamide bound in
the cytosol facing cavity of BSEP_glib is depicted. Additional densities
are in proximity to the sulfonyl group of glibenclamide and might repre-
sent coordinated water or ions. On the right a model of glibenclamide is
shown.
Figure 21: Resolution estimation of BSEPeqATP_closed: FSC curves on the left
indicate resolution estimate determined by 0.143 cutoff criterion. The
volume on the right shows local resolution estimated in relion.
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seemingly open conformation. Bundle A and bundle B have an opening angle
of 40°. This map could be refined to a resolution of 4.8Å (Figure 21). TMDs
colocalize very well with the model build in the glibenclamide bound map. Sur-
prisingly, an additional density shows up in the central cavity. This additional
density forms a helix directing from the internal to the external side, followed
by a turn induced by two succeeding prolines. A stretch of coil connects this
density to the shoulder helix starting the second half of BSEP. We refer to this
density as the connecting loop (CL) as it is part of the connection between the
N- and C-terminal half of BSEP. The ABTMpro server (SSpro/SSpro8) pre-
dicts corresponding amino acid sequence to form a α-helix in the N-terminal
and coil in the C-terminal part (Figure 22C). The sequence is clearly pre-
dicted to be not a TMD. The turn region of this additional density interacts
with residues Y772, Y1000, Y772, F83, F776, F993, F1018, N996, Q76, V368
M992, and L364. Most of these residues interact with glibenclamide in BSEP-
glib. In Proximity of the CL α-helix the helix bundles A and B separate in the
membrane area. There an additional density shows up between H4 and H6,
facing the detergent region as well. Taurocholate fits to this density, directing
the hydrophobic surface towards the very hydrophobic helix 4. The hydrox-
ygroup at position C3 points towards S249 of H4, whereas hydroxygroups at
position C7 and C12 on the hydrophilic site face the slightly more hydrophilic
helix 6 (Figure 22B and D). The conjugated taurine is surrounded by charged
residues E381 of helix 6, R696 and K700 of the CL helix, E723 and K726 of
CL coil. In NBD2 a density is present giving a potential fit of ATP. Due to
the bad local resolution in the NBDs the fit of ATP is not very good. For
simplicity we refer to this model as BSEPEQATP_CL.
3.2.4 Structure of BSEPEQATP without Taurocholate
Most particles of BSEP with an E to Q mutation bound to ATP adapt a
conformation similar to BSEPqeATP_CL. Due to the low resolution of this
map interpretation are not easy. The most interesting feature we see is the
helix of the CL sitting in the cytosolic facing cavity. The coil directing back is
not visible presumably owed to the resolution.
3.3 Discussion
3.3.1 Glycosylation of BSEP
Based on our data we conclude that in human BSEP only the first two of four
potential glycosylation sites are actually glycosylated. This is in disagreement
with biochemical experiments performed on rat BSEP in the lab of Irwin M.
Arias ([157]). In principle this inconsistency can be explained by differences
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Figure 22: (A) Density for the CL leaving the cavity and directing to glutamate
E737, the starting point of the C-terminal half of BSEP as it could be
build in the map of BSEP_glib. (B) Taurocholate placed in the density
between helix 4 and 6. (C) Secondary structure prediction of the CL
using ABTMpro. The α-helix build in our density is marked red, whereas
green marks the coil region found in BSEPeqATP_CL. The single letter
code of the prediction is H (α-helix), C (coil), E (extended strand), T
(turn), and S (bend). (D) Taurocholate sitting between helix 4 and 6.
The left panel is focusing on the hydrophobic and the right on the hy-
drophilic side. The central representation shows taurocholate positioned
in the observed binding site. The color code from blue to red indicates
the coulomb potential calculated in Chimera from blue (-10), light blue
(-5), white, light red (+5) to red (+10) in kcal/(mol·e)
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Figure 23: Resolution estimation of BSEPeqATP_CL: FSC curves on the left indi-
cate resolution estimate determined by 0.143 cutoff criterion. The volume
on the right shows local resolution estimated in relion.
Figure 24: Resolution estimation of BSEPeqATP: FSC curves on the left indicate
resolution estimate determined by 0.143 cutoff criterion. The volume on
the right shows local resolution estimated in relion.
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in glycosylation between human BSEP and the rat homolog used for the bio-
chemical approach. Another reason could be the different expression system,
as rat BSEP was expressed in MDCK II cells, whereas human BSEP for our
experiments is expressed in HEK-293 cells. Nevertheless the extracellular loop
between helix 1 and 2 is highly conserved (Figure 25A) and therefore these
prior biochemical results should be reviewed. The glycosylation profile of rat
BSEP (Figure 25B) shows a reduction in molecular weight for BSEP harbor-
ing mutated glycosylation sites. Thereby potentially glycosylated asparagine
residues were mutated to glutamine. For wild type and glycosylated versions,
a second band at a lower molecular weight appears. This band is interpreted
as core glycosylated BSEP. This represents BSEP with the initial immature
glycosylation. The same two bands are detectable in the half-life experiment,
marked as C and D band. Intriguingly, a second band is visible in the quadru-
ple mutated BSEP too (Figure 25D). Figure 25C shows expression levels of
BSEP constructs. For wild type, single and double mutant BSEP, the de-
crease in molecular weight is consistent with the assumed loss of glycans. But
For the triple mutant BSEP only the lower band initially interpreted as core
glycosylated BSEP is detectable. For quadruple mutant BSEP no band is de-
tectable. Bands of Figure 25C are not in ratio with those shown in Figure 25B.
The signal for triple and quadruple mutated BSEP in Figure 25B is too strong
compared to wild type, single and double mutant BSEP, even taking into ac-
count that sample amount for triple and quadruple mutated BSEP is 4 times
larger than for wild type, single and double mutant. We can therefore not be
sure that the bands for triple and quadruple mutants derive from the BSEP
mutant. Analysis of different numbers and combinations of mutations showed
a strong correlation between the number of mutations and expression levels.
With up to two mutations BSEP expression is still good, but not in triple
mutants. Unfortunately not all 16 combinations were tested. This implies
a pivotal stabilizing effect of N122, though we cannot see a reasoning in our
model. On the other hand a mutation of N125 has more adverse effects than
mutating N122. This is in agreement with our structure. To clarify the impact
of the four potential glycosylation sites, corresponding experiments need to be
repeated. In addition to the 16 N to Q knock out combinations, a mutation
of T124 and T127 should be tested. This would change the Asn - X - Thr/Ser
glycosylation consensus sequence of N122 and N125, without replacing the as-
paragine. Therefore potential interactions of the asparagine side chain would
stay preserved.
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Figure 25: All panels are taken from [157] (A) Sequence alignment of BSEP cov-
ering the extracellular loop between helix 1 and 2. Potential glycosyla-
tion sites are marked bold. (B) Difference of the molecular weight of
wild type BSEP and single, double, triple, and quadruple glycosylation
site KO constructs. (C) Basically the same experiment as in B, but
with equal amounts loaded in every lane. (D) Biochemical half-lives
experiment showing degradation of triple and quadruple mutant BSEP.
Quadruple mutants show an unexpected second band, which might have
been misinterpreted.
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3.3.2 BSEP Inhibition by Glibenclamide
The map of BSEP inhibited by glibenclamide on its own looks straightforward
for interpretation. BSEP is in an inward open conformation and glibenclamide
sits in the cavity, blocking either the gateway for bile salt transport or locks
BSEP in an inward open conformation. The map of BSEPEQATP_closed
supports the idea of locking the inward open conformation, as in this struc-
ture residues involved in coordinating glibenclamide are packed very tightly.
In this conformation no ligand could bind in this location. The map of
BSEPEQATP_CL on the other hand shows a direct interaction of the CL
with most residues involved in glibenclamide coordination. Assuming that the
CL is involved in the transport of bile salts, blocking access to this side by
glibenclamide represents a convincing model for inhibition.
3.3.3 Bile Salt Transport
Most reliable information for the transport of bile salts we obtain from
BSEPEQATP _CL. In this map we see densities for ATP bound to NBDs
and a single molecule of taurocholate near the BSEP-detergent interface. The
placement of taurocholate might seem unexpected at a first glance. But tak-
ing into account the detergent property of bile salts, a transport passing the
protein-lipid interface is not that unlikely. Access form the cytosolic side is
blocked by the CL reaching into the cavity formed by bundle A and B. Taken
together BSEPEQATP_CL shows BSEP in an occluded state in the middle
of a transport cycle. In BSEP_glib, neither ATP nor taurocholate is present.
The overall conformation is still similar to BSEPEQATP_CL. The main differ-
ence is the missing CL reaching into the cavity of BSEP. In fact, no density is
observable from this loop at all. This conformation is induced or stabilized by
glibenclamide blocking the CL out of the cavity. This gives a potential opening
for bile salt access. It is not clear if this structure represents a real state of
the transport cycle, stabilized by glibenclamide or if we see a non-native con-
formation induced by glibenclamide binding. Further structural data of BSEP
without ATP, taurocholate and glibenclamide could give more insight, but is
difficult to obtain due to the low stability and flexibility of BSEP in complete
absence of ligands. Based on our maps, various models can be assumed for
bile salt transport. Most promising models are illustrated in Figure 26. The
most convincing model assumes a spontaneous entry of bile salts into the in-
ner leaflet of the plasma membrane. From there bile salt can access BSEP
similar to the vacuum cleaner model ([21]). As taurocholate is still bound to
BSEP in the map of BSEPeqATP_CL we have to assume that not only ATP
binding, but also hydrolysis is required for the transport. This model would
imply that the CL is natively always in the cavity for the transport cycle and
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that the structure of BSEP_glib would therefore not represent a state of bile
salt transport. BSEPeqATP agrees with this model by showing densities for
the CL even in absence of bile salts, which is the closest model to BSEP in
apo state we have. BSEPeqATP_closed disagrees with this model unless we
assume that there exists a inactivated state of BSEP in which the CL faces
the cytosol. In addition we have to keep in mind, that in 3D classification of
BSEPeqATP and BSEPeqATP_CL we find minor classes describing a closed
conformation, which does not provide space for the CL. In principle this closed
state could represent baseline ATPase activity of BSEP in a locked state with
ATP binding inducing closure of the cytosolic cavity. A second model for bile
salt transport implies a complicated re-orientation of the CL. We assume that
in apo state the CL sits in the cytosol. A bile salt molecule binds to the CL
and thereby induces a reorientation into the cavity. From there bile salts are
exported upon ATP binding and hydrolysis. This model would assume that
the glibenclamide bound state represents the apo state. BSEPeqATP_closed
could be explained either as BSEP having bound ATP before bile salt binding
to the CL or it could be seen as an expansion of this model. Hereby bile salts
interact with the CL and translocate to the cavity. Here bile salt is released
and the CL moves back to the cytosol. Now the closing of helix bundles A
and B upon ATP binding leads to the final export. In this context BSEPe-
qATP_closed describes the state after bile salt export, unable to return to the
inward open conformation due to the lack of ATP hydrolyzing capability. This
model seems nearly too complex, but might be the reason for the extremely low
transport rate of BSEP of less than one molecule per transporter and minute,
estimated by in-vitro measurements. This model allows further assumptions
regarding bile salt transport through hepatocytes. In fish and bird the liver
bile acid binding protein (L-BABP) is supposed to shuttle bile salts across the
cytosol ([172]). L-BABP is not conserved in mammals, but the related liver
fatty acid-binding protein (FABPL) can potentially fill in. The involvement of
FABPL in transport is in question, as its deletion has no effect at normal bile
salt levels. Still the CL of BSEP might be involved in binding FABPL and
releasing shuttled bile salt. But we have to state that this model is in disagree-
ment with the map of BSEPeqATP, where the CL sits in the cavity in absence
of bile salts. The third model is very simple and assumes the direct access of
bile salt to the cavity. ATP binding then induces closure and export of bile
salts. In this model glibenclamide would block BSEP in an inward open state.
The CL has no function in this model apart of a potential inactivation of BSEP
by blocking the cytosolic cavity. This model seems quite unlikely, as gliben-
clamide makes contact to most residues interacting with the CL. Furthermore
this model can not explain the high substrate specificity of BSEP compared
to Pgp. Substrate densities of BSEPeqATP_CL clash with this model as well,
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Figure 26: Three models for bile salt transport. The models are reduced to bile salt
binding. ATP binding to NBDs is not indicated explicitly. (A) Bile salt
enters the inner leaflet of the canalicular membrane. From there bile salts
are bound by BSEP and translocate to the extracellular side, either along
the BSEP-membrane interface or through a cavity build by hydrolysis of
ATP. The CL blocks access from the cytosolic side and interacts with
bile salt. (B) In the apo state the CL faces the cytosol. Upon bile salt
binding the CL translocates into the cytosolic cavity. ATP binding and
hydrolysis leads to final bile salt export. (C) Bile salts enter the cytosolic
cavity and are transported to the extracellular side upon ATP binding.
The CL is not involved in the transportation, but might still act as a
regulator, blocking access to the cytosolic cavity.
because in this state taurocholate is present in BSEP though the CL blocks
cytosolic access.
The role of the CL in ABC-transport is unknown so far. In structures of
monomeric ABC transporters the CL remains mostly unstructured and a func-
tion in transport has not been discussed to our knowledge. Intriguingly, in the
case of BSEP mutations placed in the CL are known to trigger PFIC. There-
fore we have to assume a functional role for this domain like binding and/or
transport of cytosolic bile salts. In summary a model including bile salt entry
to BSEP though the inner leaflet or mediated by the CL are much in favor,
despite conflicts mentioned previously. Further experiments have to provide
more information to come up with more precise transport models.
66
3.3 Discussion
Figure 27: Panel A and B show interactions seen in BSEP_glib, whereas panel C
shows an interaction seen in BSEPeqATP_CL. (A) M62, W163, and
M217 connect helix1, 2, and 3 of helix bundle A. Mutation of these two
methionine provokes PFIC. (B) PFIC relevant R832 interacts with Y274
and Y304. These three residues are placed in helix bundle B. Y304 might
couple interactions of R303 with NBDs to Y274 and R832. (C) W330
(white arrow) interacts with the helical part of the CL. Mutating W330
to an arginine leads to PFIC.
3.3.4 PFIC and BRIC Related Mutations
Multiple mutations BSEP have been reported to trigger PFIC or BRIC. Mu-
tations affecting gene splicing and nonsense mutations are not to be explained
by our structure. Neither are silent mutations, which can be involved in drug
induced cholestasis. Table 2 shows a list of missense mutations , sorted accord-
ing to our models. Least interesting are mutations to a proline, like A390P or
Q869P. In this case we can assume that these prolines disrupt the secondary
structure they’re part of. We will not analyze them in more detail. Other
mutations exchange an amino acid by another one with adverse properties:
This can affect folding or stability of the transporter. Examples for this type
of mutations are G982R, T1029K and I182K. Of most interest are mutations
affecting residues showing some interactions, either with a ligand or with other
domains. These residues might be part of the transport cycle or key points in
stabilizing important domains. Due to the relative low resolution of our maps
we pinpoint only some rather clear cases as examples, indicating a potential
interaction.
Our model build into BSEP_glib shows a clear interaction of both methion-
ine M217 and M62 with tryptophan W163. These interactions connect helix
1, 2, and 3 of helix bundle A. Arginine 832 is associated with PFIC disease.
Here BSEP_glib shows an interaction with tyrosine Y304 and Y274. Espe-
cially Y304 is interesting, as preceding arginine R303 is as well associated with
PFIC and can make a potential interaction with NBD domains upon an ATP-
induced conformational change. Glycine 188 on the other hand sits in the
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loop between helix 2 and 3. It forms a cis peptide bond end enables thereby
following tryptophan W189 to interact with methionine M185 at the end of
helix 2. This leads to a very short loop connecting these two helices. Mutation
of G188 would therefore interfere with the formation of this loop and could
thereby distort the cytosolic fraction of helix 2 and 3. Tryptophan 330 could
be shown to interact with the CL in BSEPeqATP_CL. This is a strong indica-
tion for an involvement of the CL in the transport cycle. Involvement of W330
mutations in PFIC supports the idea of CL interactions in ligand transport.
R689 sits in the CL of BSEP and correlates with PFIC disease. Based on
our BSEPeqATP_CL map this residue is potentially interacting with E825.
Intriguingly both residues are conserved between BSEP and ABCB1.
3.3.5 Potential Further Experiments
So far no final model for the BSEP transport cycle can be concluded. More
structural data as well as biochemical experiments are needed to rule out wrong
transport models. An apo structure of BSEP in absence of ATP, taurocholate
and glibenclamide could answer the question, whether the CL is in the cy-
tosol in absence of any ligands. A better structure of BSEPEQ with ATP, but
without taurocholate and a structure of BSEP with taurocholate, but without
ATP would help us to match conformational features with the ligand trigger-
ing them. On the biochemical side mutations of some potential key residues
from the CL should be tested in a transport assay. Especially L706 interacting
with W330, K700 interacting with E723 sitting in the coil region of the CL,
and L712 interacting with F83 in the turn between CL helix and coil would
be interesting. Furthermore all residues having a potential interaction with
PFIC/BRIC relevant residues would be exciting. To assess a potential con-
formational change of the CL, circular dichroism spectroscopy could be used
to monitor reactions of the CL on taurocholate. To get more insight in the
glycosylation of BSEP, all 16 N to Q knock out combinations of N109, N116,
N122, and N125 should be tested. In addition point mutations at T124 and
T127 could be used to prevent glycosylation independent side effects.
3.4 Conclusion
For BSEP the goal was to obtain first structural data. We were able to gen-
erate four maps and build three models. So far the mechanism of transport is
still elusive, as no model can explain all maps we obtained. Nevertheless we
could come up with three potential transport models. Two of models give a
potential explanation for the high substrate specificity of BSEP compared to
ABCB1, by using the transport over the inner membrane leaflet or binding to
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TMD/loop BRIC type 2 PFIC type 2
Inside M1V, G19R
TMD 1 L50S, M62K, C68Y
Outside C107R, I112T, W114R
TMD 2 E135K, E137K, E186G Y157C, A167T, A167V, I182K, M183T,
M183V
Inside G188W
TMD3 L198P M217R, R223C, S226L
Outside G238V
TMD 4 T242I, A257G, V284L
Inside E297G E297G
TMD 5 R303G, R303K, Q312H, R313S, G327E,
W330R, C336S, W342G
Outside
TMD 6 G374S, A390P A382G, R387H, A390P
NBD1 A390P, R432T, V444A,
I498T, A570T, T586I,
G648V, T655I
G410D, L413W, I420T, D440E, G455E,
K461E, T463I, Q466K, R470Q, Y472C,
V481E, D482G, R487H, R487P, N490D,
I498T, G499E, I512T, N515T, R517H,
F540L, I541L, I541T, F548Y, D549V,
G556R, G562D, A570T, L581F, A588V,
S593R, I627T, E636G
CL R698C, S699P, E709K
TMD 7 G758R, G766R
Outside
TMD 8 Y818F, R832C, R832H
Inside
TMD 9 T859R, A865V, Q869P, G877R
Outside S901R
TMD 10 T923P, A926P
Inside R948C R948C
TMD 11 N979D, G982R, G1004D
Outside G1004D
TMD 12 R1050C T1029K, G1032R, A1044P
NBD2 G1116R, R1128H,
L1197G, R1231Q
L1055P, C1083Y, A1110E, S1114R,
G1116E, G1116F, G1116R, S1120N,
R1128C, S1144R, R1153C, R1153H,
S1154P, N1173D, T1210P, N1211D,
V1212F, R1231Q, R1231W, L1242I,
D1243G, R1268Q, A1283V, G1292V,
G1298R
Table 2: Missense mutations associated with benign recurrent intrahepatic cholesta-
sis and progressive familial intrahepatic cholestasis. Some mutations are
associated with both diseases. Table is adapted from ([173]).
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the connecting loop as additional selectivity filter. In regard of glycosylation
we could show that BSEP is at least glycosylated at N109 and N116. While
we cannot rule out an unlikely glycosylation of N122, N125 could be shown to
be involved in an interaction with helix 1 instead. As previous experiments
indicated a strong impact of mutations at N125, we can assume an involve-
ment of N125 in stabilization or functional rearrangement during the transport
cycle. For the inhibitor glibenclamide we describe the binding site and show
interactions of the connecting loop with the very same residues in absence of
inhibitor. Very important are structural explanations for mutations leading
to a disease state. This will help to better interpret future biochemical and
genetic data and confirms our model. Some mutations connected with BSEP
related intrahepatic cholestasis were addressed. As many questions remain
unanswered, further experiments will be needed to find the correct transport
model.
3.5 Considerations for Pgp Based on BSEP Results
Pgp and BSEP share a high sequence identity. Therefore a similar overall
structure was assumed and finally confirmed. Sequence alignments show, that
the CL of Pgp is shorter than in BSEP and most CL residues placed in the
cavity in BSEP are missing in Pgp. Therefore we have to assume that in
Pgp we cannot find the CL facing the cavity. Nevertheless CL residue R698
in BSEP shown to be sensitive to mutation and its interaction partner E825
are conserved in Pgp as R666 and E782. Q869, a second potential interaction
partner of R698 is not conserved in Pgp, but all surrounding amino acids are.
Maybe interaction is rather with the glycine backbone of G870. In regard of
the drastic effect of an R698C mutation in BSEP, an experiment in Pgp with
mutations in corresponding residues could give further insight to Pgp based
transport.
Pgp and BSEP show both a wide spread of the two helix bundles in the inward
open conformation. In case of an amphiphilic molecule a like taurocholate,
transport along the protein-membrane interface appears reasonable. For Pgp
ligands on the other hand we assume a transport path through the cavity. As
the CL of Pgp does not extend into the cavity and as transported molecules
do not show detergent characteristics, this transport model is still preferred.
Still we have to consider a possible side entry of certain ligands to the cavity.
This mode has been proposed before ([21]).
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4 Sodium Calcium Exchanger (NCX)
T his section is based on a unpublished manuscript jointly written byMark Hilge and Raphael Küng.
All steps of this work were performed by Mark Hilge and Raphael Küng
equally, with exception of data processing and the transport assay. Data
processing was mostly done by Mark Hilge and the transport assay was
performed by Raphael Küng.
Contents
4.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
4.5 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
4.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
4.7 Supplementary Figures . . . . . . . . . . . . . . . . . . . . 87
4.1 Abstract
The plasma membrane Na+/Ca2+ exchanger (NCX) removes bulk amounts of
Ca2+ from the cytosol by expelling one Ca2+ ion for the uptake of three Na+
ions. Here, we report the crystal structures describing two distinct substrate-
free states of a NCX homolog from Thermotoga maritima (NCX_Tm) in the
outward-facing conformation. While one of the forms displays entirely empty
ion binding sites, the other shows the presence of a water molecule, restricting
and rigidifying the ion binding sites. Comparison with the Na+-bound form of
a NCX homolog from Methanococcus suggests that re-orientation of the first
part of helix M7 is sufficient to form and seal ion access and exit pathways
as well as to induce the transition from the outward- to the inward-facing
conformation.
4.2 Introduction
Ca2+ is an ambivalent signal that is both essential and potentially dangerous
for cell life [174]. The accurate control of the spatio-temporal homeostasis of
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Ca2+ is achieved by the concerted interplay of Ca2+ channels, Ca2+ pumps, and
Ca2+ exchangers, located in the plasma membrane, the inner mitochondrial
membrane, and the membrane of the endoplasmic reticulum [175]; [176]. As
a high-capacity Ca2+ export system the Na+/Ca2+ exchanger (NCX) enables
muscle relaxation in the heart [177]; [178]; [179] and guarantees rapid Ca2+
fluxes, important in signaling pathways in excitable cells [180]; [181]. Making
use of the Na+ gradient established by the Na+/K+ ATPase NCX expels one
Ca2+ ion for the uptake of three Na+ ions [182]; [183]. In animals Na+/Ca2+
exchange is regulated by either Ca2+ binding to two Ca2+ binding domains
present in the intracellular exchanger loop [184]; [185]; [186] or by an interac-
tion of PIP2 [187]; [188] with a third domain referred to as catenin-like domain.
In contrast, the K+-dependent NCX (NCKX) and the NCX homologs in plants
and lower organisms lack these regulatory domains. Together they form the
cation/Ca2+ exchanger superfamily of Na+/Ca2+ and H+/Ca2+ exchangers
that was divided into five subfamilies, dubbed NCX, NCKX, YRBG, CAX,
and CCX [189]. This classification is based on the existence of two homolo-
gous, conserved regions of approximately 40 residues designated as α-1 and α-2
repeats [190]; [191]. The repeats comprise transmembrane helices M2 and M3
in the first and M7 and M8 in the second half of the cation/Ca2+ exchangers.
With the exception of those for glycine and proline, mutations of conserved
residues in the α-repeats of NCX and NCKX almost exclusively resulted in loss
of exchange activity [190]; [192]. Recently, the structure of a NCX homolog
from Methanococcus jannaschii (NCX_Mj) was determined at exceptionally
high resolution [193]. Intriguingly, the NCX_Mj structure was initially inter-
preted as a state simultaneously binding one Ca2+ and three Na+ ions, thus
contradicting the mutually-exclusive mode suggested by many transport exper-
iments [194]; [177]. Subsequent analyses using molecular dynamics indicated
that the electron density modeled by a Ca2+ ion would better accommodate a
Na+ ion and the site located opposite to it, appears to be more compatible with
a binding site for a water molecule [195]. Furthermore, from the examination
of the ion binding sites it is evident that the ion-coordinating residues consti-
tute a large part of the highly mutation-sensitive amino acids in the α-repeat
regions while the remaining conserved residues are probably required to main-
tain the binding sites. The NCX_Mj structure also revealed the symmetric
arrangement of transmembrane helices M1-M5 with respect to helices M6-M10,
thus corroborating the hypothesis that cation/Ca2+ exchangers originate from
an ancient gene duplication event [191]. To obtain a detailed understanding
of the transport mechanism of cation/Ca2+ exchangers, structural information
of as many key intermediate states as possible is essential. Presently, there is
one structure of a Na+/Ca2+ exchanger (NCX_Mj) in an outward-facing con-
formation and three structures, Vcx1 [196], CAX_Af [197], and YfkE [198],
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representing H+/Ca2+ exchangers in the inward-facing conformation. Here,
we report two new conformational states of the Na+/Ca2+ exchanger from
Thermotoga maritima (NCX_Tm), constituting the first substrate-free struc-
tures of a cation/Ca2+ exchanger. Together with the structures of the other
exchangers, we assigned the NCX_Tm structures to a specific state in the
transport cycle and propose a model for a simple alternate access mechanism,
adjusted to cation/Ca2+ exchangers.
4.3 Results
4.3.1 Functional characterization of NCX_Tm
In a GFP-fusion protein screen [199] with about thirty putative cation/Ca2+
exchangers from diverse sources NCX_Tm displayed suitable properties for
structural studies. To determine its ion selectivity we reconstituted puri-
fied NCX_Tm into lipid vesicles. These proteoliposomes were loaded with
a 25mM HEPES, pH 6.8 buffer, containing 200mM XCl (X = Na+, Li+, K+,
or NMDG+). Ca2+ import was initiated by diluting proteoliposomes into ex-
ternal buffer, consisting of 25mM HEPES, pH 6.8, 200mM NMDG-Cl, and
250μM CaCl2. To test for H+/Ca2+ exchange the pH of the external buffer
was adjusted to 7.6 and 8.2, respectively. Ca2+ accumulation within the vesi-
cles was monitored by measuring the time-dependent increase in fluorescence
as a result of Ca2+ binding to the dye Fluo-3. As an increase in fluorescence
could be detected even in the absence of an ion gradient, all measurements
were corrected for this background fluorescence. The highest rate of Ca2+
influx was observed upon application of an outwardly directed Na+ gradient,
while no transport activity could be detected in the presence of a H+ gradient
(Figure 28a and b). Tests with Li+ and K+ as counter ions displayed slower
and approximately four-fold reduced Ca2+ uptake compared to assays with
Na+. The presence of an additional, inwardly directed K+ gradient showed
no effect on Ca2+ transport (Figure 28b). In summary, the transport assay
data are consistent with the properties of a Na+/Ca2+ exchanger. To thermo-
dynamically characterize Ca2+ binding to NCX_Tm, we employed isothermal
titration calorimetry (ITC). Fitting of the integrated heat pulses suggests that
NCX_Tm binds one Ca2+ ion with an affinity of 84 ± 5μM (Figure 28c).
4.3.2 NCX_Tm structures
To get deeper insight into the Na+/Ca2+ exchange mechanism we con-
ducted vapor diffusion and liquid cubic phase crystallization experiments with
NCX_Tm. Our vapor diffusion efforts yielded two crystal forms which belong
to space group C2 and C2221, respectively. Initially, the structure of the C2
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Figure 28: Ca2+ transport and binding. (a) Counter ion selectivity of NCX_Tm-
mediated Ca2+ uptake into proteoliposomes by monitoring the increase
in fluorescence in response to Ca2+ binding to the dye Fluo-3. Transport
assays were performed for Na+, Li+, K+, and H+. To explore poten-
tial H+-coupled Ca2+ transport, pH gradients were applied employing a
luminal pH of 6.8 against an extraliposomal pH of 7.6 or 8.2. As con-
trols transport assays were conducted in the absence of a Na+ gradient
and in the presence of equimolar concentrations of NMDG-Cl. The lat-
ter measurements were subtracted from all other experiments to account
for Ca2+ contaminations in the buffers and potential Ca2+ leakage. (b)
An additional inwardly directed K+ gradient was applied to evaluate
the possibility of a K+-dependent NCX. All experimental details con-
cerning the transport assays can be found in Supplementary Table 3. (c)
Thermodynamic characterization of NCX_Tm using isothermal titration
calorimetry (ITC). The top graph displays the recorded heat pulses, ob-
served upon injection of 1μl of 3mM Ca2+ containing buffer, while the
data points in the bottom graph are the result of the integration of the
heat pulses. Fitting of the data points yields the binding isotherm, the
stoichiometry, and the binding constant.
crystal form was determined by molecular replacement using the coordinates
of NCX_Mj [193]. The structure of the C2221 crystal form was obtained us-
ing the C2 crystal structure as search model. The C2 and C2221 structures
were refined using data to 3.5 and 3.55Å, respectively. In both crystal forms,
NCX_Tm crystallizes as a dimer with both protomers in the same orientation,
adopting an outward-facing conformation (Figure 29a). This arrangement was
also found in four additional crystal forms, we investigated. The overall dif-
ferences between the protomers are relatively subtle. However, the two crystal
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forms display marked differences in their ion binding sites. In particular, in
the C2 form no electron density was observed for multiple side chains, which
are strictly conserved among NCX and were shown to be crucial for ion co-
ordination [193]. Furthermore, there is no indication for substrate binding in
the electron density at positions where ions bind in the NCX_Mj structure
(Figure 29b). Taken together, the structure of the C2 crystal form appears to
be compatible with a substrate-free state. In comparison, with the exception
of Glu215 the side chains of the ion-coordinating residues in the structure of
the C2221 crystal form are visible in the electron density. At the position sim-
ilar to the binding site previously referred to as Na+mid a density peak above
1σ in the 2Fo-Fc and above 3σ in the Fo-Fc map is observed (Figure 29c).
However, there is no electron density indicative of the coordination of a Ca2+
ion or a Na+ ion at a location comparable to Na+int or Na+ext. In contrast
to the C2 crystal form, the binding sites of the C2221 form are considerably
more restricted. For instance, the distance between the Cα atoms of Pro50
and Pro214, strictly conserved residues preceding the Ca2+ coordinating glu-
tamates in NCX and NCKX, is 2Å shorter and comparable with the distance
found in NCX_Mj. This suggests that the initial binding of a water molecule
brings helices M2 and M7 closer together at the ion binding sites.
4.3.3 Structural comparison with NCX_Mj
Superposition of the structure of NCX_Mj onto the structure of the C2 crys-
tal form shows an rmsd of 1.58Å on 235 Cα positions. Aside the deviations
at the N- and C-termini and regions before and after the central disordered
loop (Figure 29a), the most prominent difference is observed for the position
of helix M7a that is rotated by approximately 43° in NCX_Mj with respect to
NCX_Tm. As a result helix M7 is bent in NCX_Mj, but kinked in NCX_Tm
(Figure 30a). Examination of the surroundings of helix M7a in NCX_Tm and
NCX_Mj reveals a relative paucity of hydrogen bonds and van der Waals in-
teractions with the remainder of the protein. A similar, albeit less pronounced
re-orientation is found for the symmetry-related helix M2a in H+/Ca2+ ex-
changers in the inward-facing conformation, between the Ca2+ bound struc-
ture of Vcx1 [196] and the fully protonated form of CAX_Af [197] (Figure 32).
Helices M1 and M6 are somewhat detached from the helical core that com-
prises the environment for the ion binding sites. While they superimpose well
for a large part of their length deviations of 2.5 and 1.5Å are observed at the
end of helix M6 and the beginning of helix M1, probably as a consequence of
the distinct positions of helix M7a in NCX_Tm and NCX_Mj (Figure 30b).
Close inspection of generally conserved residues in helices M2 and M7 that are
not directly involved in ion coordination, reveals predominately hydrophobic
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Figure 29: Overall structure and ion binding sites of NCX_Tm in the outward-
facing conformation. (a) Dimeric structure of NCX_Tm with protomer
A shown in red and protomer B in rose. The highly acidic central loop is
disordered and indicated by red dashes. The salt-bridges between Lys119
and Asp127 are highlighted in the blow-up. (b) Empty ion binding sites
of the C2 crystal form. Positions, at which ions bind in the NCX_Mj
structure, are indicated by dashed circles. (c) Occupied binding site
opposite to the empty Na+mid site in the C2221 crystal form. The 2Fo-Fc
and Fo-Fc maps are contoured at 1σand 3σ, respectively. All structural
figures were generated in PyMOL
interactions with non-conserved residues in helix M6. In NCX_Tm, Leu49,
Pro50, and Val53, located in helix M2 at the center of the ion binding sites,
form extensive van der Waals interactions mostly with Ile174 and Trp178 in
helix M6 (Figure 30c). In contrast, the corresponding residues in helix M7,
Leu213, Pro214, and Val217, maintain a comparably reduced number of hy-
drophobic interactions. In NCX_Mj, with the ion binding sites occupied by
three Na+ ions, the situation is reversed, i.e. the corresponding residues in
helix M7, but not those in M2, maintain numerous van der Waals contacts
with residues in helix M6.
4.3.4 Ion pathway analysis of NCX_Tm and related cation/Ca2+ exchanger
structures
To support an assignment of the NCX_Tm structures to specific states in the
transport cycle of cation/Ca2+ exchangers we performed ion pathway analyses
using the program MOLE 2.0 [200]. As a starting point for the calculations,
we chose Glu51 and Glu215 at the center of the ion binding sites. For both
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Figure 30: Conformational changes in bacterial Na+/Ca2+ exchangers in the
outward-facing conformation upon Na+ binding. (a) Re-orientation of
helix M7a between NCX_Tm (red) and NCX_Mj (grey) in response to
Na+ binding. (b) Impact of Na+ binding on helices M6 and M1 as well as
the hydrophobic interactions (c) with helix M6 for NCX_Tm (red) and
NCX_Mj (grey). (d) Ion pathway analysis of the NCX_Tm structures
using the program MOLE 2.0 [200]. The tunnel detected in protomer A
of the C2 crystal form is colored yellow. The graph on the right shows the
tunnel radius as a function of the distance to Glu51, which was chosen
as a starting point for the calculations.
NCX_Tm structures, the calculations revealed an approximately 17Å long
pathway that gradually widens towards the surface of the exchanger (Fig-
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ure 30d). Strikingly, application of the same parameters as used in the cal-
culations for the NCX_Tm structures, yields, in disagreement with previous
suggestions [193], no ion pathways for NCX_Mj. To extend the ion pathway
analysis to the entire transport cycle we also performed the corresponding
calculations with identical parameter settings to the available, superimposed
H+/Ca2+ exchanger structures in the inward-facing conformation (Figure 33).
For each protomer at least one ion pathway could be detected. While the pro-
tomers of CAX_Af and YfkE display similar pathway diameters, substantially
different profiles were found for the Ca2+ bound protomers of Vcx1.
4.3.5 Dimer interface and 2nd Ca2+ binding site
In contrast to the dimers found in the asymmetric units of the Vcx1 and
CAX_Af structures, there are several lines of evidence that protomers A and
B form a physiological dimer in NCX_Tm. First, both protomers display the
same orientation in the NCX_Tm crystal structures (Figure 29a). Thereby,
protomers A and B interact via an interface of 1001Å−2. Its main feature is
Lys119, which forms a salt-bridge with Asp127 in the other protomer. Second,
analyses using multi-angle light scattering (SEC-MALS) suggest a tetramer
for wild-type NCX_Tm (Figure 31b), but predominantly only a dimer for the
K119A and K119E mutants (Supplementary Fig. 3). The additional dimeriza-
tion may be explained by the interaction of the N- and C-termini of one dimer
with the corresponding termini of another dimer, resulting in an arrangement
found in the C2 and C2221 crystal forms. Aside its importance in dimer for-
mation, intriguingly the NZ group of Lys119 coincides with a second Ca2+
binding site in NCX1 and NCKX2. Conserved mutations of residues Asp121
and Asp127 that coordinate the second Ca2+ ion, resulted in non-functional
canine NCX1 [190] and human NCKX2 [192]. In the case of NCX_Mj a cor-
responding second Ca2+ binding site is found on the extracellular side in the
loop connecting helices M4 and M5, whereas in the H+/Ca2+ exchangers, an
analogous second Ca2+ binding site is found on the cytosolic side between
helices 9 and 10 in the Vcx1 and CAX_Af structures, but not in the YfkE
structure, determined at pH 4. To assess the potential relevance of Lys119 in
the exchange mechanism as an alternative to the second Ca2+ binding site in
other cation/Ca2+ exchangers, we analyzed the K119A and K119E mutants
by means of the proteoliposomal transport assay, previously used for wild-type
NCX_Tm. As no differences in activity could be observed in the transport
assays for the mutants compared to wild-type NCX_Tm (Figure 31c), the
function of the second Ca2+ binding site remains enigmatic.
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Figure 31: Characterization of the Lys119 mutants in the dimer interface. (a) Ther-
modynamic characterization of the K119A mutant by ITC. The top graph
displays the recorded heat pulses, while the data points in the bottom
graph are the result of the integration of the heat pulses. Fitting of
the data points yields the binding isotherm, the stoichiometry, and the
binding constant. (b) SEC-MALS analysis performed at 6°C. Results
of the SEC-MALS experiments of the Lys119 mutants can be found in
Supplementary Figure 34. (c) Ca2+ transport properties of the K119A
and K119E mutants with respect to wild-type NCX_Tm.
4.4 Discussion
Bioenergetically, protons are the most common coupling ions in bacterial trans-
port. However, some bacteria utilize, similarly to animals, a Na+ gradient for
coupled transport [201]. With the help of transport assays based on proteoli-
posomes we demonstrate that NCX_Tm, like NCX_Mj, is a Na+/Ca2+ ex-
changer. In contrast, the structurally characterized Vcx1, CAX_Af, and YfkE
were shown to be H+/Ca2+ exchangers. This raises the question whether it
would be possible to predict the nature of the counter ion from the primary
sequence. Comparison of residues involved in ion coordination in the avail-
able Na+/Ca2+ exchanger structures reveals that Thr50, Ser51, Thr209, and
Ser210 are generally conserved in the large body of intensively studied mam-
malian NCX and NCKX, but are absent in the H+/Ca2+ exchanger structures.
These four residues crucially coordinate the Na+int and Na+ext ions via the free
electron pairs of their hydroxyl groups. The importance of these residues in
Na+ binding and their conservation in the YRBG subfamily of cation/Ca2+
exchangers, suggests that its members can probably be regarded as bacterial
Na+/Ca2+ exchangers. In comparison a high percentage of H+/Ca2+ exchang-
ers show conservation of the GNxxE motif in the α-repeats. In the Ca2+
bound Vcx1 structure the conserved Gly102, Asn103, Gly298, and Asn299
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form hydrogen bonds to three water molecules that assist the coordination
of the Ca2+ ion. In contrast, the distantly related CAX_Af represents a mi-
nority of H+/Ca2+ exchangers and possesses instead of the conserved glycine
and asparagine residues two additional acidic residues, Asp82 and Glu25, in
the ion binding sites. Hence, the presence of either the GNxxE motif or two
additional acidic residues in the center of helices M2 and M7 is indicative
of a H+/Ca2+ exchanger. To get a detailed overview of the entire transport
cycle of cation/Ca2+ exchangers we made an attempt to assign each of the
presently available structures to a specific state in the cycle. Thereby, we pre-
dominantly based our assignment on the angle between helices M2 and M7a in
the outward- and the angle between helices M2a and M7 in the inward-facing
conformation, the presence of a tunnel and the substrates bound to the ex-
changers. In the C2 crystal form of NCX_Tm disordered side chains of the
ion-coordinating residues, the absence of bound Na+ or Ca2+ ions, a kinked
helix M7 and wide ion binding sites are compatible with a substrate-free con-
formation (state 1). The C2221 crystal form of NCX_Tm displays an occupied
water binding site. In contrast to the entirely empty sites of the C2 crystal
form, the water binding appears to bring helices M2 and M7 closer together
and causes a rigidification of side chains of the ion-coordinating residues with
the exception of the side chain of Glu215 (state 2). Probably upon occupa-
tion of the external Na+ binding site Comparison of the substrate-bound form
of NCX_Tm with the NCX_Mj structure suggests that the interactions of
the strictly conserved Thr211 and Ser212 with the third Na+ ion lead to a
re-orientation of helix M7a. This transition is probably facilitated by the rel-
ative paucity of interactions of residues in helix M7a with the remainder of
NCX_Tm and NCX_Mj. As a consequence, the kinked helix M7, present in
NCX_Tm, is converted into a bent helix as found in NCX_Mj. While tunnel
analyses of the two states of NCX_Tm reveal very similar profiles for their ion
access/exit pathways, no ion pathway could be identified in NCX_Mj, thus
suggesting an occluded state (state 3). The re-orientation of helix M7a also ap-
pears to alter the interactions of in NCX and NCKX conserved apolar residues
with residues in helix M6. Directly located at the ion binding sites, Leu49,
Pro50, and Val53 in helix M2 of the substrate-free states of NCX_Tm form
numerous hydrophobic interactions with residues in helix M6, which are mostly
absent in NCX_Mj. Instead, as a sort of compensation, NCX_Mj maintains
van der Waals interactions between Leu211, Pro212, and Val215 in helix M7
with non-conserved apolar residues in helix M6 (Figure 30c). Consequently,
the end of helix M6 and the beginning of helix M1 are relocated accordingly
(Figure 30b). In analogy to the state-dependent positions of helix M7a in the
outward-facing conformations of NCX_Tm and NCX_Mj, comparable orien-
tations are observed for the symmetry-related helix M2a in the inward-facing
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conformations of the CAX structures. As helices M2b and M7b are consid-
erably less affected by substrate binding, we superimposed the structures of
the outward- onto the inward-facing conformations, using these constant re-
gions of helices M2 and M7 as alignment anchors. This structural alignment
reveals that at least the end of helix M7a in NCX_Mj and the beginning
of helix M2a in CAX_Af adopt positions similar to the same helices in the
oppositely oriented inward- and outward-facing conformations. Hence the re-
orientation of helix M7a, accompanied by small adjustments in the position of
helix M6 and even smaller changes with respect to helix M1 (Figure 30b), is
sufficient to close the extracellular ion pathway(s) in NCX_Mj. However, al-
though protomer A of CAX_Af is fully protonated and its helix M2 maintains
a conformation very close to the one of helix M2 in NCX_Tm and NCX_Mj,
the exchanger from Archaeoglobus does not constitute an occluded state, but
rather reflects a state either immediately before or after due to the presence of
an ion pathway (state 4). Protomer B of CAX_Af shows the same orientation
for helices M2 and M7 as protomer A, however probably as a consequence of
the unprotonated state of Glu258 wider ion binding sites. Similarly to the
orientation of helix M7 in states 1 and 2 in the outward-facing conformation
the structures of Ca2+ bound Vcx1 possess a kinked helix M2 (state 5). Fi-
nally, the structure of YfkE, obtained from crystals grown at pH 4, probably
represents an inactive or locked state as His256 occupies a position normally
maintained by the Ca2+ coordinating Glu255. The outlined model for trans-
port is depicted in Figure 35. Despite the increasing number of cation/Ca2+
exchanger structures shedding more and more light on the mechanism of the
transport cycle, several questions, especially those regarding the exact location
of the Ca2+ binding site and how Ca2+ binding can induce the transition from
the inward- to the outward-facing conformation, remain. Furthermore, there
is presently no explanation for the relatively large differences in the orientation
of helices M1 and M6 between the outward- and inward-facing conformations.
As there are no conserved residues in these helices varying conformations may
also be attributed to differences between Na+/Ca2+ and H+/Ca2+ exchangers.
Our study has revealed the first substrate-free structures of a cation/Ca2+
exchanger in the outward-facing conformation. Comparison with the previ-
ously reported structures of cation/Ca2+ exchangers the NCX_Tm structures
suggest that re-orientation of helix M7a is basically sufficient to seal the ex-
tracellular pathways. In agreement with the high turnover rates reported for
mammalian NCX [202]; [177] such a simple mechanism could provide the basis
for an alternate access mechanism, generally expected for cation/Ca2+ ex-
changers.
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4.5 Methods
4.5.1 Cloning, screening and expression
To identify cation/Ca2+ exchangers suitable for structural studies we cloned
20 genes encoding putative bacterial and mammalian Na+/Ca2+ as well as ten
fungal and plant H+/Ca2+ exchangers using a ligation independent cloning
(LIC) approach. For efficiency purposes we utilized a modified pGAPZ vec-
tor to create C-terminal GFP fusion constructs for expression in Pichia pas-
toris. Exchanger expression levels were monitored by in-gel fluorescence anal-
ysis of 2ml cultures, harvested at different optical densities. In this screen the
Na+/Ca2+ exchanger of Thermotoga maritima (NCX_Tm) was identified as a
promising candidate for structural studies. Solubilization efficiency and deter-
gent compatibility was assessed by fluorescence size-exclusion chromatography
[203]; [199]. Best results with respect to stability and monodispersity were ob-
tained with 5-cyclohexyl-1-pentyl-β-D-maltoside (CYMAL-5 ANAGRADE®,
Anatrace). For large-scale expressions and the establishment of a purifica-
tion protocol the C-terminal GFP-tag, fused to full-length NCX_Tm (309
residues, UniProt accession code: Q9WZI3) was replaced by a Strep-II-tag
(WSHPQFEK). As a relict of the 5’ LIC primer this construct contained four
non-coding residues, MLFQ, at the N-terminus.
4.5.2 Purification
A pre-culture of 10ml, grown at 30°C in the presence of 1mg of
zeocin™(InvivoGen), was used to inocculate 4L of YPD medium (Invitrogen
Pichia pastoris User Manual). At an OD600 of 8-10 cells were harvested by
centrifugation. For crude membrane preparation cell pellets were dissolved
in buffer A (50mM Tris, pH 8.0, 10% glycerol) supplemented with 300mM
NaCl, 10mM β-mercaptoethanol, 1mM benzamidine, DNAse I, and Complete
EDTA-free protease inhibitors (Roche). Cells were broken by performing ten
passes through an M-110P Microfluidizer (Microfluidics) applying 20’000 PSI.
After removal of the cell debris by centrifugation (11’000g for 30min), crude
membranes were harvested by ultracentrifugation at 195’000g for 3h. To re-
move membrane-associated contaminants the crude membranes were washed
in buffer A supplemented with 1M NaCl and 5mM β-mercaptoethanol and
were pelleted at 195’000g for another 3h. The washed crude membranes
were then solubilized in buffer B (50mM Tris, pH 8.0, 300mM NaCl, 5mM
β-mercaptoethanol) supplemented with 20mM n-dodecyl-β-D-maltopyranoside
(DDM SOL-GRADE®, Anatrace) for 3h. Subsequently, insoluble parts were
removed by centrifugation at 70’000g for 1h and the cleared, solubilized ex-
tract was exposed to buffered streptactin beads for 2h using gentle rotation.
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The beads were collected in a Biorad Econo column and the flow-through was
re-loaded three times to increase the binding efficiency of NCX_Tm. After
washing the beads with 13 column volumes of buffer B supplemented with
6mM CYMAL-5, NCX_Tm was eluted with the wash buffer containing 5mM
desthiobiotin. For crystallization NCX_Tm was first concentrated to a vol-
ume of 500μl, washed twice with 50mM Tris, pH 8, 300mM NaCl and 6mM
CYMAL-5, and was finally concentrated to 9-12mg/ml using a 50kDa cut-
off filter (Amicon® Ultra-4). To remove potential aggregates the NCX_Tm
concentrate was ultracentrifuged at 220’000g for 20min. All purification steps
were performed at 4°C.
4.5.3 Crystallization
By mixing 100nl of concentrated NCX_Tm with 100nl of reservoir solution
using the standard MemStart, MemSys, and MemGold screens (Molecular Di-
mensions) several initial hits in vapor diffusion crystallization experiments were
obtained at 20°C. From the crystal forms we investigated two forms diffracted
to approximately 3.5Å resolution. Crystals of form 1 belonged to space group
C2 and grew in the presence of 100mM Na+ citrate, pH 4.75-5.5, 200mM
(NH4)2SO4, and 33-36% PEG 200. These either rod- or plate-like crystals ap-
peared after 30 days and reached their final dimensions of up to 500 × 100
× 10μm within 60 days. Crystals of form 2 belonged to space group C2221
and were obtained with reservoir solution containing 100mM Na+ citrate, pH
5.0, 100mM Li2SO4, and 10-10.5% PEG 4000. These cat eye-like crystals were
generally visible after ten days and grew to full dimensions of 200 x 100 x 20μm
within a few days. While crystallization conditions of the C2 crystal form al-
ready included a cryoprotectant, freezing of the C2221 crystals required the
addition of 30% ethylene glycol. All crystal forms investigated diffracted X-
rays anisotropically and substantial efforts to obtain more isotropic diffraction
failed.
4.5.4 Structure determination
All data sets were collected from frozen crystals at the X06SA beamline at
the Swiss Light Source of the Paul Scherrer Institut using a PILATUS 6M de-
tector. The data were indexed and integrated with XDS [204] while merging
of the data was carried out with aimless [205] within the CCP4 suite [206].
Anisotropy correction [207] was carried out in Phaser [208] prior to structure
determination of the C2 crystal form by molecular replacement (MR). The best
MR solution was obtained using the coordinates of the Na+/Ca2+ exchanger
from Methanococcus jannaschii (pdb code: 3V5U) [193] and was initially re-
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fined with phenix.mr_rosetta [209]. The NCX_Tm structure was then further
improved in several alternating rounds of model building in COOT and refine-
ment using PHENIX [144] and Buster-TNT [210], employing two-fold NCS
restraints, restrained individual B factors and TLS. Despite the anisotropic
data the electron density of the C2 form was of high quality and resulted in
a model comprising good geometry. The structure of the C2221 crystal form
was determined using the C2 structure as a search model, while refinement was
carried out analogously to the C2 structure. Rfree was calculated by select-
ing 10% of the reflection data that were omitted throughout the refinement.
The final structures of the C2 and C2221 crystal forms have R/Rfree values of
0.330/0.370 and 0.285/0.331.
4.5.5 Reconstitution and transport assay
Liposomes were prepared by mixing chloroform stocks of 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-
3-[phospho-rac-(1-glycerol)] (POPG), and 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine (POPE) at a 3:1:1 ratio. Prior to dissolving the lipids
in PBS buffer (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4)
chloroform was evaporated. For NCX_Tm reconstitution liposomes were soni-
cated, extruded through a 400nm filter using a mini-extruder for large unilam-
inar vesicles (Avanti), and destabilized with Triton X-100. Purified NCX_Tm
(1mg/ml) was then mixed with the liposomes at a ratio of 1:50. After removal
of the detergent with the bio-beads, the proteoliposomes were fractionated and
stored at -80°C [211]. To determine the counter-ion specificity of NCX_Tm
the PBS buffer of the proteoliposomes was changed to 25mM HEPES, pH 6.8
buffer supplemented with 100μM of the fluorescent dye Fluo-3 (F-1240, Fisher
Scientific), 200mM NMDG+ or 200mM of XCl where X is either Na+, K+,
or Li+. To load the vesicles, the proteoliposomes were briefly sonicated, sub-
jected to three freeze/thaw cycles, and extruded through a 200nm filter. To
remove the fluorescent dye outside the vesicles, proteoliposomes were pelleted
by centrifugation at 21’000g for 90min and re-suspended in the buffer used to
load the vesicles. This washing step was repeated four times. Finally, the pro-
teoliposomes were aliquoted at a concentration of 100mg/ml. The transport
assays were performed in black, flat-bottom 96-well plates using a Synergy
H1 fluorescence plate-reader. Thereby, 4μl of proteoliposomes were diluted in
200μl of external buffer (for details see Table 3). The initial three minutes of
the experiments were used to determine the baseline. Ca2+ uptake into the
vesicles was initiated by the addition of 250μM CaCl−2 to the external buffer
and the change of fluorescence was monitored during 1h. To equilibrate the
Ca2+ concentration across the proteoliposomal membrane, calcimycin to a fi-
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nal concentration of 100nM was added. This allowed for the normalization
of the fluorescence data using the baseline before CaCl2 addition and the sig-
nal of the saturated dye after calcimycin addition. To correct for background
fluorescence, values obtained with a "zero-gradient" experiment employing a
25mM HEPES, pH 6.8 200mM NMDG inside and outside of the vesicle, were
subtracted from each experiment. Measurements were performed in triplicate
with the standard errors of the mean indicated by error bars. All buffers used
in the transport assays were prepared with Ca2+-free water (H2OMB0501,
Merck Millipore) and residual Ca2+ was chelated by appropriate amounts of
EGTA, which were estimated by measuring the fluorescence of the dye fluo-3
in the corresponding buffers.
4.5.6 Isothermal titration calorimetry (ITC)
NCX_Tm (wild-type and mutants) samples for ITC measurements were
prepared using Ca2+-free water and high-quality chemicals to minimize the
amount of contaminating Ca2+ ions. Protein concentrations were deter-
mined using a Nanodrop® spectrophotometer ND-1000 (Isogen Life Science)
and were 254μM and 150μM in the case of wild-type NCX_Tm and mutant
NCX_K119A, respectively. Metal salts were prepared in the same buffers as
the corresponding protein samples. ITC experiments were carried out with
an ITC200 (Microcal LLC) device. Following thermal equilibration at 293K,
38 serial injections of 1μl were performed at 500 rpm stirring speed with an
injection spacing of 3min. Constructs were measured at least three times to
determine the optimal experimental conditions with respect to signal-to-noise
ratio and the number of data points. In all cases, experiments were consistent
and reproducible. To correct the experimental binding isotherm for back-
ground heat effects, we also titrated CaCl2 containing buffer into buffer. Data
were analyzed with the "one set of sites" model implemented in the Origin 7.0
software.
4.5.7 Multi-angle light scattering (SEC-MALS)
SEC-MALS [212] experiments were performed at 6°C using a 5/150 Superdex
S200 column (GE Healthcare) equilibrated in 50mM Tris, pH 8.0, 300mM
NaCl, 5mM β-mercaptoethanol and 6mM CYMAL-5, on an Agilent 1260
HPLC system with a Wyatt Heleos 2 8-angle light-scattering detector and
a Wyatt Optilab Rex differential refractive index detector. Signal align-
ment, band-broadening correction and detector normalization were performed
according to the manufacturers instructions, using bovine serum albumin
monomer (Sigma Aldrich) in the experimental buffer. For the analysis of
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purified NCX_Tm or the K119A mutant, 50μl samples were injected. Weight-
average molecular weights for protein and detergent components were deter-
mined for each point in the chromatogram by global fitting of light-scattering,
UV absorbance at 280nm, and differential refractive index data, using the
protein conjugate analysis method in the Wyatt Astra 6 package.
4.6 Conclusion
Our NCX project provides a first apo conformation. This helps to fill up
gaps in the current list of available conformations. In addition our model
gives the first structural evidence for a dimerization of a Na+/Ca2+ exchanger.
However we have to assume that this is a feature of the Termotoga maritima
NCX homolog. In a transport assay we shower that NCX_Tm is actually
a real Na+/Ca2+ exchanger like NCX_Mj, and not a H+/Ca2+ exchanger as
assumed. Sequence alignments could show common features, which might
help to predict the counter ion for other NCX homologs. Based on structures
available up to date, we propose a very simple model of alternative access. This
model is in line with the high exchange rate of NCX. In contrary to alternative
models conformational changes of helix 1 and 6 are not considered to be part
of the transport cycle.
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4.7 Supplementary Figures
Figure 32: Conformational changes in H+/Ca2+ exchangers in the inward-facing con-
formation. Superposition of helices M2 and M7 of Ca2+ bound Vcx1
(blue) and fully protonated CAX_Af (light blue).
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Measurement Inside Outside
Na 200mM NaCl 50mM HEPES
pH 6.8
200mM NMDG 50mM HEPES
pH 6.8
Na/K 200mM NaCl 50mM HEPES
pH 6.8
200mM NMDG 50mM HEPES
pH 6.8
200mM KCl
No gradient
(Na)
200mM NaCl 50mM HEPES
pH 6.8
200mM NaCl 50mM HEPES
pH 6.8
pH 7.6 200mM NMDG 50mM HEPES
pH 6.8
200mM NMDG 50mM HEPES
pH 7.6
pH 8.2 200mM NMDG 50mM HEPES
pH 6.8
200mM NMDG 50mM HEPES
pH 8.2
No gradient
(NMDG)
200mM NMDG 50mM HEPES
pH 6.8
200mM NMDG 50mM HEPES
pH 6.8
pH 7.6/K 200mM NMDG 50mM HEPES
pH 6.8
200mM NMDG 50mM HEPES
pH 7.6
200mM KCl
No gradient
(NMDG)/K
200mM NMDG 50mM HEPES
pH 6.8
200mM NMDG 50mM HEPES
pH 6.8
200mM KCl
K gradient 200mM KCl 50mM HEPES
pH 6.8
200mM NMDG 50mM HEPES
pH 6.8
Li gradient 200mM LiCl 50mM HEPES
pH 6.8
200mM NMDG 50mM HEPES
pH 6.8
Liposomes 200mM NaCl 50mM HEPES
pH 6.8
200mM NMDG 50mM HEPES
pH 6.8
Table 3: For three minutes the baseline was determined. After the addition of 250μM
CaCl2 the change of fluorescence was recorded for 1h. Then 100nM cal-
cimycin was added to equilibrate [Ca2+] over the proteoliposoms. Recorded
data were scaled using the baseline before CaCl2 addition and the signal
of saturated dye after calcimycin addition. All measurements were done
three times. Standard error of the mean (N=3) are given for all measuring
points. Buffers for the transport assay were prepared with Ca-free wa-
ter (Millipore) and residual Ca2+ was complexed with 20μM EGTA. Free
[Ca2+] was estimated by measuring fluo-3 saturation in the corresponding
buffer.
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Figure 33: Ion pathway analysis of cation/Ca2+ exchanger structures Vcx1, Cax_Af,
and YfkE.
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Figure 34: SEC-MALS analyses of the K119A and K119E mutants. Derived molec-
ular weights for the protein alone (red dots) and in complex with the
detergent (blue dots) were obtained. In contrast to wild-type NCX_Tm
not only a single species is observed, likely influencing the molecular
weight calculations.
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Figure 35: Transport model for NCX. Helix M2 and M7 are shown in green and blue
respectively. Structures corresponding to a state are indicated. In cases
a structure represents an intermediate of depicted states, corresponding
structure is noted in between.
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5 Conclusions
T his thesis covered three projects for which we aimed to get deeperstructural and functional understanding. The project on P-glycoprotein
was accomplished and provided new insights. We provide the first occluded
model of Pgp. In addition we identified and described binding sites of the
third generation inhibitor zosuquidar. This can potentially help to generate
new generations of optimized inhibitors. Furthermore we could show that
paclitaxel is able to abrogate ATPase stimulation. Finally we described
the conformational epitope of UIC2, an antibody capable to inhibit Pgp.
The structure of ABCB1HM−EQ-UIC2 I contributed was not used for model
building, but it served as a link between the cross-linked ABCB1HM−X-UIC2
and the not solved structure of human ABCB1. The similar overall structure
supports the models obtained from the strongly modified constructs. The
low resolution of ABCB1HM−EQ-UIC2 is attributed to the high flexibility in
absence of a crosslink.
For BSEP the goal was to obtain first structural data. We were able to
generate four maps and build three models. So far the mechanism of transport
is still elusive, as no model can explain all maps we obtained. Nevertheless
we could come up with three potential transport models. Two of models
give a potential explanation for the high substrate specificity of BSEP
compared to ABCB1, by using the transport over the inner membrane leaflet
or binding to the connecting loop as additional selectivity filter. In regard
of glycosylation we could show that BSEP is at least glycosylated at N109
and N116. While we cannot rule out an unlikely glycosylation of N122, N125
could be shown to be involved in an interaction with helix 1 instead. As
previous experiments indicated a strong impact of mutations at N125, we can
assume an involvement of N125 in stabilization or functional rearrangement
during the transport cycle. For the inhibitor glibenclamide we describe the
binding site and show interactions of the connecting loop with the very same
residues in absence of inhibitor. Very important are structural explanations
for mutations leading to a disease state. This will help to better interpret
future biochemical and genetic data and confirms our model. Some mutations
connected with BSEP related intrahepatic cholestasis were addressed. As
many questions remain unanswered, further experiments will be needed to
find the correct transport model.
Our NCX project provides a first apo conformation. This helps to fill up
gaps in the current list of available conformations. In addition our model
gives the first structural evidence for a dimerization of a Na+/Ca2+ exchanger.
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However we have to assume that this is a feature of the Termotoga maritima
NCX homolog. In a transport assay we shower that NCX_Tm is actually
a real Na+/Ca2+ exchanger like NCX_Mj, and not a H+/Ca2+ exchanger as
assumed. Sequence alignments could show common features, which might
help to predict the counter ion for other NCX homologs. Based on structures
available up to date, we propose a very simple model of alternative access. This
model is in line with the high exchange rate of NCX. In contrary to alternative
models conformational changes of helix 1 and 6 are not considered to be part
of the transport cycle.
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